IMV (IMVIF) 40-F 1 Apr 19 2018 FY Annual report (Canada) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2018shares
Document And Entity Information
Entity Registrant Name	IMV Inc.
Entity Central Index Key	0001734768
Document Type	40-F
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current?	Yes
Is Entity Emerging Growth Company?	true
Elected Not To Use the Extended Transition Period	false
Entity Common Stock, Shares Outstanding	45,106,401
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 14,895	$ 14,909
Amounts receivable (note 5)	1,337	261
Prepaid expenses	2,699	838
Investment tax credits receivable	1,111	461
Total Current assets	20,042	16,469
Property and equipment (note 6)	2,883	563
Total Assets	22,925	17,032
Current liabilities
Accounts payable and accrued liabilities (note 7)	7,575	2,760
Amounts due to directors (note 10)	49	21
Current portion of long-term debt (note 11)	81	61
Current portion of lease obligation (note 8)	90
Total Current liabilities	7,795	2,842
Lease obligation (note 8)	1,308
Deferred share units (note 9)	1,436	1,371
Long-term debt (note 11)	8,069	6,476
Total Liabilities	18,608	10,689
Equity	4,317	6,343
Total liabilities and equity	$ 22,925	$ 17,032

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - CAD ($) $ in Thousands	Share Capital [Member]	Contributed Surplus [Member]	Warrants [Member]	Deficit [Member]	Total
Balance at Dec. 31, 2016	$ 58,154	$ 6,961	$ 660	$ (58,792)	$ 6,983
Net loss and comprehensive loss for the period				(12,027)	(12,027)
Issuance of shares in public offering	10,000				10,000
Share issuance costs	(1,197)				(1,197)
Issuance of broker warrants			208		208
Exercise of warrants	1,891		(194)		1,697
Employee share options:
Value of services recognized		571			571
Exercise of options	1,265	(1,157)			108
Balance at Dec. 31, 2017	70,113	6,375	674	(70,819)	6,343
Net loss and comprehensive loss for the period				(21,935)	(21,935)
Issuance of shares in public offering	14,375				14,375
Share issuance costs	(1,480)				(1,480)
Redemption of DSUs, net of applicable taxes	220				220
Issuance of broker warrants			332		332
Exercise of warrants	5,480		(591)		4,889
Employee share options:
Value of services recognized		1,182			1,182
Exercise of options	1,444	(1,053)			391
Balance at Dec. 31, 2018	$ 90,152	$ 6,504	$ 415	$ (92,754)	$ 4,317

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue
Subcontract revenue	$ 82	$ 33
Interest revenue	401	189
Total Revenue	483	222
Expenses
Research and development	12,852	5,938
General and administrative	7,241	5,202
Government assistance	(1,062)	(1,078)
Business development and investor relations	2,002	1,221
Accreted interest (note 11)	1,385	966
Total Expenses	22,418	12,249
Net loss and comprehensive loss for the year	$ (21,935)	$ (12,027)
Basic and diluted loss per share	$ (0.50)	$ (0.31)
Weighted-average shares outstanding	43,766,951	38,656,771

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash provided by (used in) Operating activities
Net loss and comprehensive loss for the year	$ (21,935)	$ (12,027)
Charges to operations not involving cash
Depreciation of property and equipment	325	140
Stock-based compensation	1,182	571
Deferred share unit compensation	508	1,147
Interest on lease obligation	94
Accreted interest	1,385	966
Revaluation of long-term debt		(506)
Loss on disposal of assets	8
Charges to operations not involving cash	(18,433)	(9,709)
Net change in non-cash working capital balances related to operations
(Increase) decrease in amounts receivable	(1,076)	8
Increase in prepaid expenses	(616)	(369)
(Increase) decrease in investment tax credits receivable	(650)	38
Increase in accounts payable and accrued liabilities	3,570	1,055
Increase (decrease) in amounts due to directors	28	(19)
Cash provided by (used in) Operating activities	(17,177)	(8,996)
Financing activities
Proceeds from issuance of share capital and warrants	14,375	10,000
Share and warrant issuance costs	(1,148)	(990)
Proceeds from the exercise of stock options	391	109
Proceeds from the exercise of warrants	4,889	1,698
Incentive contribution from lessor	896
Proceeds from long-term debt	300
Withholdings on redemption of DSUs	(223)
Repayment of long-term debt	(72)	(72)
Repayment of lease obligation	(74)
Cash provided by (used in) financing activities	19,334	10,745
Investing activities
Acquisition of property and equipment	(2,185)	(387)
Proceeds from sale of assets	14
Cash provided by (used in) investing activities	(2,171)	(387)
Net change in cash and cash equivalents during the year	(14)	1,362
Cash and cash equivalents - Beginning of year	14,909	13,547
Cash and cash equivalents - End of year	14,895	14,909
Supplementary cash flow
Interest received	$ 401	$ 189

Nature of operations

Nature of operations	12 Months Ended
	Dec. 31, 2018
Disclosure of nature of operations [Abstract]
Nature of operations	1 Nature of operations IMV Inc. (the “Corporation”, “IMV”, formerly “Immunovaccine Inc.”) is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Corporation’s proprietary drug delivery platform (“DPX”). This patented technology leverages a novel mechanism of action (“MOA”) discovered by the Corporation. This MOA does not release the active ingredients at the site of injection but forces an active uptake and delivery of active ingredients into immune cells and lymph nodes. It enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. DPX no release MOA can be leveraged to generate “first-in-class” T cell therapies with the potential to be transformative in the treatment of cancer. The Corporation has research collaborations with companies and research organizations, including Merck, Incyte Corporation and Leidos Inc. in the U.S. The Corporation has licensed the delivery technology to Zoetis, formerly the animal health division of Pfizer, Inc., for the development of vaccines for livestock. The Corporation has one reportable and geographic segment. Incorporated under the Canada Business Corporations Act and domiciled in Dartmouth, Nova Scotia, the shares of the Corporation are listed on the Nasdaq Stock Market and the Toronto Stock Exchange under the symbol “IMV”. On May 1, 2018, the Corporation changed its name from Immunovaccine Inc. to IMV Inc. The address of its principal place of business is 130 Eileen Stubbs, Suite 19, Dartmouth, Nova Scotia, Canada.

Basis of presentation

Basis of presentation	12 Months Ended
	Dec. 31, 2018
Disclosure of basis of presentation [Abstract]
Basis of presentation	2 Basis of presentation The Corporation prepares its consolidated financial statements in accordance with Canadian generally accepted accounting principles as set out in the Chartered Professional Accountants of Canada Handbook – Accounting Part I (“CPA Canada Handbook”), which incorporates International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). These consolidated financial statements were approved by the Board of Directors on March 21, 2019.

New standards and interpretatio

New standards and interpretations adopted January 1, 2018	12 Months Ended
	Dec. 31, 2018
New Standards And Interpretations Adopted January 1 2018 Schedule Of Operating Lease Commitment
New standards and interpretations adopted January 1, 2018	3 New standards and interpretations adopted January 1, 2018 IFRS 9, Financial Instruments Effective January 1, 2018, the Corporation was required to adopt IFRS 9. IFRS 9 replaces the provisions of IAS 39, Financial instruments: recognition and measurement Prior to January 1, 2018, all of the Corporation’s financial instruments were measured using the amortized cost model. At the date of adoption, the Corporation’s financial assets consisted of amounts receivable from collaborative partners for shared clinical costs, and financial liabilities consisted of trade payables and long-term debt arrangements. There is no difference between the categorization of these financial assets and financial liabilities under IFRS 9 and IAS 39 and, accordingly, all such assets and liabilities continue to be measured using the amortized cost model. The Corporation was required to revise its impairment methodology for financial assets under IFRS 9, and now applies the simplified approach to measuring the new concept of expected credit losses, which uses a lifetime expected loss allowance for all trade receivables. Management determined that the effect of applying this model to its financial assets is immaterial and, therefore, no adjustment has been made to the loss allowance as at January 1, 2018. There was no impact on the January 1, 2018 statement of financial position as a result of the adoption of this standard. IFRS 15, Revenue from contracts with customers The Corporation was required to adopt IFRS 15 effective January 1, 2018. The modified retrospective method was applied for transition to this standard, under which the cumulative impact of initially applying the standard is recognized as an adjustment to the opening balance of retained earnings. The Corporation also elected to apply the practical expedient whereby contracts that were completed at the beginning of the earliest period presented need not be considered for restatement. The Corporation currently generates revenue from providing formulation services to its collaborative partners. No adjustment to opening retained earnings was required as a result of the adoption of this standard based on management’s analysis of the performance obligations related to existing contracts of the Corporation. Refer to note 4 for further details on the Corporation’s revenue recognition policies. IFRS 16, Leases The Corporation also early adopted IFRS 16, Leases Previously, at the inception of a contract, the Corporation determined whether an arrangement contains a lease under IAS 17. Under IFRS 16, the Corporation assesses whether a contract is or contains a lease based on the definition of a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Corporation assesses whether: the contract involves the use of an identified asset, specified either explicitly or implicitly, that is physically distinct, and usage represents substantially all of the capacity of the asset; the Corporation has the right to obtain substantially all of the economic benefits from use of the asset; and the Corporation has the right to direct use of the asset, which is evidenced by decision-making rights to direct how and for what purpose the asset is used. The Corporation recognizes an asset and a lease liability at the lease commencement date. The asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred, less any incentives received. The asset is subsequently depreciated using the declining balance method from the commencement date to the earlier of the end of the useful life of the asset or the end of the lease term. The estimated useful lives of leased assets are determined on the same basis as those of property and equipment. The carrying amount of the leased asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability, if any. The lease liability is initially measured at the present value of future lease payments, discounted using the interest rate implicit in the lease, or, if that rate cannot be readily determined, the Corporation’s incremental borrowing rate. Generally, the Corporation uses its incremental borrowing rate as the discount rate. The lease liability is subsequently measured at amortized cost using the effective interest method. It is remeasured if the Corporation changes its assessment of whether it will exercise a purchase, extension, or termination option. If the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the leased asset, or is recorded in the consolidated statement of loss and comprehensive loss if the carrying value of the leased asset is zero. The Corporation has elected not to recognize assets and lease liabilities for short-term leases with a term of 12 months or less, and leases of low value assets. The lease payments associated with these leases are recognized as an expense in the consolidated statement of loss and comprehensive loss over the lease term. Low value assets consist primarily of computers and IT equipment. This policy is applied for contracts entered into, or changed, on or after January 1, 2018. For contracts entered into before January 1, 2018, the Corporation determined whether the arrangement was or contained a lease based on the assessment of whether: fulfilment of the arrangement was dependent on the use of specific assets; and the arrangement conveyed a right to use the asset. An arrangement conveyed the right to use the asset if the Corporation had the ability to control physical access to the asset and how and for what purpose the asset was used. Under IAS 17, leases that transferred substantially all the risks and rewards of ownership were classified as finance leases. When this was the case, the leased assets were measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. The Corporation did not have any leases that were classified as finance leases under IAS 17. All other leases were classified as operating leases and were not recognized in the Corporation’s statement of financial position. Payments made under operating leases were recognized in the consolidated statement of loss and comprehensive loss over the term of the lease. Application expedients and impact on financial statements On transition to IFRS 16, the Corporation elected to apply the practical expedient to grandfather the assessment of which transactions are leases. IFRS 16 was applied only to contracts that were previously identified as leases. Contracts that were not identified as leases under IAS 17 were not reassessed for whether there is a lease. The Corporation used the following practical expedients when applying IFRS 16 to leases previously classified as operating leases under IAS 17: Applied a single discount rate to a portfolio of leases with similar characteristics; Applied the exemption not to recognize assets and lease liabilities for leases with less than 12 months of lease term remaining at the application date; and Used hindsight when determining the lease term if the contract contains options to extend or terminate the lease. On transition, the Corporation applied section C8(b)(ii) of the standard and recognized leased assets at an amount equal to the lease liability, adjusted for prepaid or accrued lease payments recognized before initial application, of which there were none. As a result, $87 of leased assets in property and equipment and $87 of lease liabilities were recognized at January 1, 2018. When measuring lease liabilities, the Corporation discounted lease payments using its incremental borrowing rate at the date of adoption. The rate applied is 11%. $ Operating lease commitment as at December 31, 2017 1 275 Recognition exemption for: Short-term leases (131 ) Leases of low value assets (14 ) Commitments attributable to non-lease components (65 ) Extension option reasonably certain to be recognized 2 51 116 Discounted using the incremental borrowing rate at January 1, 2018 (29 ) Lease liability recognized at January 1, 2018 87 1 2 The leased assets and liabilities recognized are for the Corporation’s office spaces that were previously classified as operating leases. These leases typically run for periods of five to ten years, and include an option to renew the lease for an additional period. When reasonably certain that the Corporation will exercise the extension option, the lease payments for the extension have been included in determining the value of the leased asset and liability shown above. Some leases also provide for additional rent payments that relate to property taxes levied on the lessor and operating expense payments made by the lessor; these amounts are generally determined annually and are expensed through the consolidated statement of loss and comprehensive loss.

Significant accounting policies

Significant accounting policies, judgments and estimation uncertainty	12 Months Ended
	Dec. 31, 2018
Disclosure of significant accounting policies, judgments and estimation uncertainty [Abstract]
Significant accounting policies, judgments and estimation uncertainty	4 Significant accounting policies, judgments and estimation uncertainty Basis of measurement The consolidated financial statements have been prepared under the historical cost convention. Consolidation The financial statements of the Corporation consolidate the accounts of IMV Inc. and its subsidiary. All intercompany transactions, balances and unrealized gains and losses from intercompany transactions are eliminated on consolidation. There are no non-controlling interests, therefore, all loss and comprehensive loss is attributable to the shareholders of the Corporation. Foreign currency translation i) Functional and presentation currency Items included in the consolidated financial statements of the Corporation are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The consolidated financial statements are presented in Canadian dollars, which is the Corporation’s functional currency. ii) Transactions and balances Foreign currency translation of monetary assets and liabilities, denominated in currencies other than the Corporation’s functional currency, are converted at the rate of exchange in effect at the consolidated statement of financial position date. Income and expense items are translated at the rate of exchange in effect at the transaction date. Translation gains or losses are included in determining income or loss for the year. Foreign exchange loss of $139 of for the year ended December 31, 2018 (2017 - $10 gain) is included in general and administrative expenses. Cash and cash equivalents Cash and cash equivalents include cash on hand, balances with banks, and highly liquid temporary investments that are readily convertible to known amounts of cash. Financial instruments Financial assets and liabilities are recognized when the Corporation becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Corporation has transferred substantially all risks and rewards of ownership. Financial assets and liabilities are offset and the net amount is reported in the consolidated statement of financial position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously. The Corporation recognizes financial instruments based on their classification. Depending on the financial instruments’ classification, changes in subsequent measurements are recognized in net loss and comprehensive loss. The Corporation has implemented the following classifications: Cash and cash equivalents and amounts receivable are classified as amortized cost (previously loans and receivables). After their initial fair value measurement, they are measured at amortized cost using the effective interest method; and Accounts payable and accrued liabilities, amounts due to directors and long-term debt are classified as other amortized cost (previously financial liabilities). After their initial fair value measurement, they are measured at amortized cost using the effective interest method. Impairment of financial assets The Corporation applies the simplified method of the expected credit loss model required under IFRS 9. Under this method, the Corporation estimates a lifetime expected loss allowance for all receivables. Receivables are written off when there is no reasonable expectation of recovery. If there is objective evidence that an impairment loss has been incurred, the amount of the loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows. The present value of the estimated future cash flows is discounted at the financial asset’s original effective interest rate. Property and equipment Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Corporation and the cost can be measured reliably. The carrying amount of a replaced asset is derecognized when replaced. Repairs and maintenance costs are charged to the consolidated statement of loss and comprehensive loss during the year in which they are incurred. Depreciation of property and equipment is calculated using the declining-balance method at the following annual rates: Computer equipment 30% Computer software 100% Furniture and fixtures 20% Laboratory equipment 20% Leasehold improvements and leased premises straight-line Residual values, method of depreciation and useful lives of the assets are reviewed annually and adjusted if appropriate. Gains and losses on disposals of property and equipment are determined by comparing the proceeds with the carrying amount of the asset and are included as part of general and administrative expenses in the consolidated statement of loss and comprehensive loss. Property and equipment and intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of measuring recoverable amounts, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units or CGUs). The recoverable amount is the higher of an asset’s fair value less the costs to sell, and value in use (being the present value of the expected future cash flows of the relevant asset or CGU). An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The Corporation evaluates impairment losses for potential reversals when events or circumstances warrant such consideration. Income tax Income tax is comprised of current and deferred income tax. Income tax is recognized in the consolidated statement of loss and comprehensive loss except to the extent that it relates to items recognized directly in equity, in which case the income tax is also recognized directly in equity. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted, at the end of the reporting period, and any adjustment to tax payable in respect of previous years. In general, deferred income tax is recognized in respect of temporary differences including non-refundable investment tax credits, arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined on a non-discounted basis using tax rates and laws that have been enacted or substantively enacted at the consolidated statement of financial position date and are expected to apply when the deferred income tax asset or liability is settled. Deferred income tax assets are recognized to the extent that it is probable that the assets can be recovered. Deferred income tax is provided on temporary differences arising on investments in subsidiaries and associates, except in the case of subsidiaries, where the timing of the reversal of the temporary difference is controlled by the Corporation and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred income tax assets and liabilities are presented as non-current. Research and development All research costs are expensed in the period incurred. Development costs are expensed in the period incurred, unless they meet the criteria for capitalization, in which case, they are capitalized and then amortized over the useful life. Development costs are written off when there is no longer an expectation of future benefits. Revenue recognition Revenues are recognized as the Corporation satisfies its performance obligations under the terms of the contract. Performance obligations are considered to be satisfied when the customer obtains control of the related asset. Current and expected future revenue streams include: (i) milestone payments generated upon entering into potential contractual partnerships and achieving development and sales milestones; (ii) future royalties generated from the eventual commercialization of the Corporation’s products; and (iii) amounts generated for providing formulation and research support services related to existing licensing and research agreements with partners. Revenue resulting from formulation services is recognized in the accounting period in which the formulation is delivered to the customer. Typically, the customer does not have control of the asset while services are being performed and, therefore, revenues are recognized at the time the Corporation has completed its obligation and the customer obtains control of the asset. Revenue resulting from research support services is recognized over time as the services are performed, as the customer benefits simultaneously from the service as the Corporation satisfies its performance obligation. The Corporation expects to generate upfront payments, milestone and royalty revenues from future licenses for the Corporation’s products. Upfront payments and milestones will be recognized as revenue when or as the underlying obligations are achieved and are not conditional on any further performance, which could be at a point in time or over time depending on the contractual terms. Royalty revenue will be recognized in the period in which the Corporation earns the royalty. The Corporation does not generate licensing or royalty revenues at this time. Share capital Common shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognized as a deduction from share capital. Loss per share Basic loss per share (“LPS”) is calculated by dividing the net loss for the year attributable to equity owners of the Corporation by the weighted average number of common shares outstanding during the year. Diluted LPS is calculated by adjusting the weighted average number of common shares outstanding for dilutive instruments. The number of shares included with respect to options, warrants and similar instruments is computed using the treasury stock method. Diluted LPS is equal to the LPS as the Corporation is in a loss position and all securities, comprised of options and warrants, would be anti-dilutive. Stock-based compensation plan The Corporation grants stock options to certain employees and non-employees. Starting January 1, 2018, stock options vest over three years (33 1/3% per year) and expire after five years. Each tranche in an award is considered a separate award with its own vesting period and grant date fair value. Fair value of each tranche is measured at the date of grant using the Black-Scholes option pricing model. Compensation expense is recognized over the tranche’s vesting period by increasing contributed surplus based on the number of awards expected to vest. The number of awards expected to vest is reviewed at least annually, with any impact being recognized immediately. A holder of an option may, rather than exercise such option, elect a cashless exercise of such option payable in common shares equaling the amount by which the value of an underlying share at that time exceeds the exercise price of such option or warrant to acquire such share. Deferred share unit plan The Corporation grants deferred share units (“DSUs”) to members of its Board of Directors, who are not employees or officers of the Corporation. All DSUs awarded vest immediately and cannot be redeemed until the holder is no longer a director of the Corporation. All services received in exchange for the grant of DSUs are measured at their fair values. The redemption value of a DSU will be based on the market value of the Corporation’s common shares at the time of redemption. On an ongoing basis, the Corporation values its liability with respect to DSUs at the current market value of a corresponding number of common shares and records any increase or decrease in the DSU obligation. Compensation expense is recognized at each grant date in general and administrative expenses on the consolidated statement of loss and comprehensive loss. Government assistance Government assistance consists of non-repayable government grants, from a number of government agencies and the difference between the fair value and the book value of repayable low-interest government loans, recorded initially at fair value. Government assistance is recorded in the period earned using the cost reduction method and is included in government assistance on the consolidated statement of loss and comprehensive loss. At December 31, 2018, $7 (2017 - $10) of government assistance is included in amounts receivable. Research and development tax credits Refundable investment tax credits relating to scientific research and experimental development expenditures are recorded in the accounts in the fiscal period in which the qualifying expenditures are incurred provided there is reasonable assurance that the tax credits will be realized. Refundable investment tax credits, in connection with research and development activities, are accounted for using the cost reduction method and included in government assistance on the statement of loss and comprehensive loss. Amounts recorded for refundable investment tax credits are calculated based on the expected eligibility and tax treatment of qualifying scientific research and experimental development expenditures recorded in the Corporation’s consolidated financial statements. Critical accounting estimates and judgments The Corporation makes estimates and assumptions concerning the future that will, by definition, seldom equal actual results. The following are the estimates and judgments applied by management that most significantly affect the Corporation’s consolidated financial statements. The following estimates and judgments have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. Calculation of initial fair value and carrying amount of long-term debt Atlantic Innovation Fund (“AIF”) loans The initial fair value of the AIF loans is determined by using a discounted cash flow analysis for each of the loans, which require a number of assumptions. The difference between the face value and the initial fair value of the AIF loans is recorded in the consolidated statement of loss and comprehensive loss as government assistance. The carrying amount of the AIF loans requires management to adjust the long-term debt to reflect actual and revised estimated cash flows whenever revised cash flow estimates are made or new information related to market conditions is made available. Management recalculates the carrying amount by computing the present value of the estimated future cash flows at the original effective interest rate. Any adjustments are recognized in the consolidated statement of loss as accreted interest after initial recognition. The significant assumptions used in determining the discounted cash flows include estimating the amount and timing of future revenue for the Corporation and the discount rate. As the AIF loans are repayable based on a percentage of gross revenue, if any, the determination of the amount and timing of future revenue significantly impacts the initial fair value of the loan, as well as the carrying value of the AIF loans at each reporting date. The expected revenue streams include i) estimated royalties generated from the eventual commercialization of the Corporation’s products, and ii) estimated milestone payments generated upon entering into potential contractual partnerships and achieving development and sales milestones. The amount and timing of estimated milestone payments forecasted are earlier and less predictable, therefore, changes in the amount and timing of milestone payments could have a significant impact on the fair value of the loans. Further, the Corporation is in the early stages of research for its product candidates; accordingly, determination of the amount and timing of any revenue streams requires significant judgment by management. The discount rate determined on initial recognition of the AIF loans is used to determine the present value of estimated future cash flows expected to be required to settle the debt. In determining the appropriate discount rates, the Corporation considered the interest rates of similar long-term debt arrangements with similar terms. The AIF loans are repayable based on a percentage of gross revenue, if any; accordingly, finding financing arrangements with similar terms is difficult and management was required to use significant judgment in determining the appropriate discount rates. Management used a discount rate of 35% to discount the AIF loans. If the weighted average discount rate used in determining the initial fair value and the carrying value at each reporting date of all AIF loans, with repayment terms based on future revenue, had been determined to be higher by 10%, or lower by 10%, the carrying value of the long-term debt at December 31, 2018 would have been an estimated $728 lower or $1,036 higher, respectively. A 10% increase or decrease in the total forecasted revenue would not have a significant impact on the amount recorded for the loans. If the total forecasted revenue were reduced to $nil, no amounts would be forecast to be repaid on the AIF loans, and the AIF loans payable at December 31, 2018 would be recorded at $nil, which would be a reduction in the AIF loans payable of $3,193. If the timing of the receipt of forecasted future revenue was delayed by two years, the carrying value of the long-term debt at December 31, 2018 would have been an estimated $1,440 lower. Province of Nova Scotia (“The Province”) The initial fair value of the Province loan is determined by using a discounted cash flow analysis for the loan. The interest rate on the loan is below the market rate for a commercial loan with similar terms. The significant assumption used in determining the discounted cash flows is the discount rate. Any changes in the discount rate would impact the amount recorded as initial fair value of the long-term debt and the carrying value of the long-term debt at each reporting date. In determining the appropriate discount rate, the Corporation considers the interest rates of similar long-term debt arrangements with similar terms. The Province loan is a government loan with principal payments only required at the end of seven years; accordingly, finding financing arrangements with similar terms is difficult and management was required to use significant judgment in determining the appropriate discount rates. Management used a discount rate of 11% to discount the Province loan. If the discount rate used for the Province loan had been determined to be higher or lower by 5% (resulting in discount rates of 16% or 6%, respectively), the carrying value of the long-term debt at December 31, 2018 would have been an estimated $325 lower or $353 higher, respectively. The difference between the book value and the initial fair value of the Province loan is recorded in the consolidated statement of loss as government assistance on initial recognition. Any changes in the amounts recorded on the consolidated statement of financial position for the Province loan result in an offsetting charge to accreted interest after initial recognition in the consolidated statement of loss.

Amounts receivable

Amounts receivable	12 Months Ended
	Dec. 31, 2018
Trade and other current receivables [abstract]
Amounts receivable	5 Amounts receivable 2018 2017 $ $ Amounts due from government assistance and government loans 7 10 Sales tax receivable 557 151 Revenue from subcontracts 33 10 Other 740 90 1,337 261

Property and equipment

Property and equipment	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [abstract]
Property and equipment	6 Property and equipment Computer equipment Leasehold and Furniture Laboratory Leased improve- software and fixtures equipment Premises ments Total $ $ $ $ $ $ Year ended December 31, 2017 Opening net book value 43 17 256 – – 316 Additions 73 15 282 – 17 387 Disposals Cost (9 ) – – – – (9 ) Accumulated depreciation 9 – – – – 9 Depreciation for the year (50 ) (5 ) (79 ) – (6 ) (140 ) Closing net book value 66 27 459 – 11 563 At December 31, 2017 Cost 205 85 1,166 – 17 1,473 Accumulated depreciation (139 ) (58 ) (707 ) – (6 ) (910 ) Net book value 66 27 459 – 11 563 Year ended December 31, 2018 Opening net book value 66 27 459 – 11 563 Additions 79 171 217 1,417 782 2,666 Disposals Cost (9 ) (61 ) (37 ) – – (107 ) Accumulated depreciation 7 47 31 – – 85 Depreciation for the year (47 ) (21 ) (112 ) (94 ) (50 ) (325 ) – – – Closing net book value 96 163 558 1,323 743 2,883 At December 31, 2018 Cost 275 194 1,346 1,417 800 4,032 Accumulated depreciation (179 ) (31 ) (788 ) (94 ) (57 ) (1,149 ) Net book value 96 163 558 1,323 743 2,883

Accounts payable and accrued li

Accounts payable and accrued liabilities	12 Months Ended
	Dec. 31, 2018
Trade and other current payables [abstract]
Accounts payable and accrued liabilities	7 Accounts payable and accrued liabilities 2018 2017 $ $ Trade payables 5,282 1,683 Accrued liabilities 2,275 1,057 Payroll taxes 18 20 7,575 2,760

Lease obligation

Lease obligation	12 Months Ended
	Dec. 31, 2018
Disclosure of finance lease and operating lease by lessee [abstract]
Lease obligation	8 Lease obligation Amount $ Balance – December 31, 2017 – Leases recognized upon transition to IFRS 16 87 Additions 1,291 Repayment of lease obligation (74 ) Accreted interest 94 Balance – December 31, 2018 1,398 Less: Current portion (90 ) Non-current portion 1,308 The Corporation recognizes a right-of-use asset and lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the liability, discounted at an incremental borrowing rate of 11%, adjusted for any payments made before the commencement date, plus any initial direct costs, less any lease incentives received. During the nine months ended December 31, 2018, the Corporation recognized $1,417 (2017 - $nil) in right-of-use assets in property, plant and equipment on the statements of financial position.

Deferred share units (DSUs)

Deferred share units (DSUs)	12 Months Ended
	Dec. 31, 2018
Deferred Share Units Dsus Schedule Of Deferred Share Units
Deferred share units ("DSUs")	9 Deferred share units (“DSUs”) The maximum number of common shares which the Corporation is entitled to issue from Treasury in connection with the redemption of DSUs granted under the DSU Plan is 468,750 common shares. The number of DSUs disclosed below reflect the retrospective application of the share consolidation completed May 2, 2018 (see note 22). DSU activity for the year ended December 31, 2018 and the year ended December 31, 2017 are as follows: December 31, December 31, 2018 2017 Number Number Opening balance 186,330 101,563 Granted 97,072 84,767 Redeemed (59,798 ) – Closing balance 223,604 186,330 At December 31, 2018, there were 223,604 (December 31, 2017 - 186,330) DSUs outstanding related to this Plan and the total carrying amount of the liability was $1,436 (2017 - $1,371). The compensation expense for the year ended December 31, 2018 was $508 (2017 - $325) with the amortization of the cost over the vesting period. Vested DSUs cannot be redeemed until the holder is no longer a member of the Board. The redemption value of a DSU equals the market value of an IMV Inc. common share at the time of redemption. On an ongoing basis, the Corporation values the DSU obligation at the current market value of a corresponding number of IMV Inc. common shares and records any increase or decrease in the DSU obligation as an expense on the consolidated statements of loss and comprehensive loss.

Amounts due to directors

Amounts due to directors	12 Months Ended
	Dec. 31, 2018
Disclosure of amounts due to directors [Abstract]
Amounts due to directors	10 Amounts due to directors During the year ended December 31, 2018, the Corporation incurred $206 (2017 - $163) of directors’ fees and attendance fees earned by the members of the Board of Directors who are not employees or officers of the Corporation. At December 31, 2018, $49 (2017 - $21) was due to these individuals. These costs are included in general and administrative expenses in the consolidated statements of loss and comprehensive loss.

Long-term debt

Long-term debt	12 Months Ended
	Dec. 31, 2018
Borrowings [abstract]
Long-term debt	11 Long-term debt 2018 2017 $ $ Atlantic Canada Opportunities Agency (“ACOA”) Atlantic Innovation Fund interest-free loan with a maximum contribution of $3,786. Annual repayments, commencing December 1, 2008, are calculated as a percentage of gross revenue for the preceding fiscal year, at 2% when gross revenues are less than $5,000 and 5% when gross revenues are greater than $5,000. As at December 31, 2018, the amount drawn down on the loan, net of repayments, is $3,744 (2017 - $3,747). 1,202 758 ACOA Atlantic Innovation Fund interest-free loan with a maximum contribution of $3,000. Annual repayments, commencing December 1, 2011, are calculated as a percentage of gross revenue for the preceding fiscal year, at 2% when gross revenues are less than $5,000 and 5% when gross revenues are greater than $5,000. As at December 31, 2018, the amount drawn down on the loan is $2,995 (2017 - $2,997). 1,034 651 ACOA Business Development Program, interest-free loan with a maximum contribution of $395, repayable in monthly payments beginning October 2015 of $3 until October 2017 and $6 until September 2022. As at December 31, 2018, the amount drawn down on the loan, net of repayments, is $251 (2017 - $318). 238 294 ACOA Atlantic Innovation Fund interest-free loan with a maximum contribution of $2,944, annual repayments commencing September 1, 2014, are calculated as a percentage of gross revenue from specific product(s) for the preceding fiscal year, at 5% for the first 5 year period and 10%, thereafter. As at December 31, 2018, the amount drawn down on the loan is $2,944 (2017 - $2,944). 957 733 TNC 120-140 Eileen Stubbs Ltd. (the “Landlord”) loan, with a maximum contribution of $300,000, bearing interest a t 8% annum, is repayable in monthly payments beginning upon receipt of the final installment of the loan until May 31, 2028. The loan is made available in three equal installments based on the Corporation meeting certain milestones. As at December 31, 2018, the amount drawn down on the loan is $300 (2017 - $ nil). 300 – Province of Nova Scotia “The Province” secured loan with a maximum contribution of $5,000, interest bearing at a rate equal to the Province’s cost of funds plus 1%, compounded semi-annually and payable monthly. The loan is made available in four equal installments based on the Corporation meeting certain milestones, and is repayable on the seventh anniversary date of the first disbursement. The Corporation and its subsidiary have provided a general security agreement granting a first security interest in favour of the Province of Nova Scotia in and to all the assets of the Corporation and its subsidiary, including the intellectual property. As at December 31, 2018, the amount drawn down on the loan is $5,000 (2017 - $5,000). 4,419 4,101 8,150 6,537 Less: Current portion 81 61 8,069 6,476 Total contributions received, less amounts that have been repaid as at December 31, 2018, is $15,234 (2017 -$15,007). Certain ACOA loans and the Province loan require approval by ACOA or the Minister for the Province before the Corporation can pay management fees, bonuses, dividends or other distributions, or before there is any change of ownership of the Corporation. The Province loan requires the Corporation to obtain the written consent of the Province prior to the sale, disposal or abandonment of possession of the intellectual property of the Corporation or its subsidiary. If during the term of the Province loan, the head office, research and development facilities, or production facilities of the Corporation are moved from the Province, the Corporation is required to repay 40% of the outstanding principal of the loan. In August 2017, the Corporation received a two-year extension of the maturity of the Province loan. The original maturity date of the loan was August 9, 2018 and is now August 9, 2020. The annual interest rate remains at the Province's cost of funds plus 1 per cent. The Province loan requires certain early repayments if the Corporation’s subsidiary, or the Corporation on a consolidated basis, has cash flow from operations in excess of $1,500,000. The Province loan also requires repayment of the loan under certain circumstances, such as changes of control, sale or liquidation of the Corporation or the sale of substantially all of the assets of the Corporation. The minimum annual principal repayments of long-term debt over the next five years, excluding the Atlantic Innovation Fund repayments for 2019 and beyond which are not determinable at this time, are as follows: $ Year ending December 31, 2019 81 2020 4,286 2021 90 2022 78 2023 31 2018 2017 $ $ Balance – Beginning of year 6,537 6,149 Borrowings, net of $nil (2017 - $nil) allocated to government assistance 300 – Accreted interest 1,385 966 Revaluation of long-term debt – (506 ) Repayment of debt (72 ) (72 ) Balance – End of year 8,150 6,537 Less: Current portion 81 61 Non-current portion 8,069 6,476 The Corporation is in compliance with its debt covenants.

Share capital

Share capital	12 Months Ended
	Dec. 31, 2018
Disclosure of classes of share capital [abstract]
Share capital	12 Share capital Authorized Unlimited number of common shares and preferred shares, issuable in series, all without par value. Number of common shares Amount $ Issued and outstanding Balance – December 31, 2016 36,817,328 58,154 Issued for cash consideration, net of issuance costs 2,403,846 8,803 Stock options exercised 316,538 1,265 Warrants exercised 782,229 1,891 Balance – December 31, 2017 40,319,941 70,113 Issued for cash, net of issuance costs 2,246,094 12,895 Stock options exercised 480,754 1,444 DSUs redeemed 29,713 220 Warrants exercised 2,029,899 5,480 Balance – December 31, 2018 45,106,401 90,152 As at December 30, 2018, a total of 1,890,539 shares (December 31, 2017 - 3,771,968) are reserved to meet outstanding stock options, warrants and deferred share units. On February 15, 2018, the Corporation completed a bought deal public offering of 2,246,094 common shares at a price of $6.40 per common share, for aggregate proceeds of $14,375. Total costs associated with the offering were $1,480, including cash costs for commissions of $863, professional fees and regulatory costs of $285, and 134,766 compensation warrants issued as commissions to the agents valued at $332. Each compensation warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $6.53 for a period of 24 months, expiring on February 15, 2020. On June 21, 2017, the Corporation completed a bought deal public offering of 2,403,846 common shares at a price of $4.16 per common share, for aggregate proceeds of $10,000. Total costs associated with the offering were $1,197, including cash costs for commissions of $600, professional fees and regulatory costs of $391, and 144,231 compensation warrants issued as commissions to the agents valued at $208. Each compensation warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $4.22 for a period of 24 months, expiring on June 21, 2019. The per share amounts disclosed above reflect the retrospective application of the share consolidation completed May 2, 2018 (see note 22).

Contributed surplus

Contributed surplus	12 Months Ended
	Dec. 31, 2018
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Contributed surplus	13 Contributed surplus Amount $ Contributed surplus Balance – December 31, 2016 6,961 Share-based compensation – stock options vested 571 Warrants expired – Stock options exercised (1,157 ) Balance – December 31, 2017 6,375 Share-based compensation – stock options vested 1,182 Stock options exercised (1,053 ) Balance – December 31, 2018 6,504 Stock options The Board of Directors of the Corporation has established a stock option plan (the "Plan") under which options to acquire common shares of the Corporation are granted to directors, employees and other advisors of the Corporation. The maximum number of common shares issuable under the Plan shall not exceed 3,437,500, inclusive of all shares presently reserved for issuance pursuant to previously granted stock options. If any option expires or otherwise terminates for any reason without having been exercised in full, or if any option is exercised in whole or in part, the number of shares in respect of which option expired, terminated or was exercised shall again be available for the purposes of the Plan. Stock options are granted with an exercise price determined by the Board of Directors, which is not less than the market price of the shares on the day preceding the award. The term of the option is determined by the Board of Directors, not to exceed ten years from the date of grant, however, the majority of options expire in five years. The vesting of the options is determined by the Board and beginning, January 1, 2018, is typically 33 1/3% every year after the date of grant. In the event that the option holder should die while he or she is still a director, employee or other advisor of the Corporation, the expiry date shall be 12 months from the date of death of the option holder, not to exceed the original expiry date of the option. In the event that the option holder ceases to be a director, employee or other advisor of the Corporation other than by reason of death or termination, the expiry date of the option shall be the 90th day following the date the option holder ceases to be a director, employee or other advisor of the Corporation, not to exceed the original expiry date of the option. The fair values of stock options are estimated using the Black-Scholes option pricing model. During the year ended December 31, 2018, 619,505 stock options (2017 - 266,813) with a weighted average exercise price of $6.65 (2017 - $2.40) and a term of five years (2017 - five years), were granted to employees and consultants. The expected volatility of these stock options was determined using historical volatility rates and the expected life was determined using the weighted average life of past options issued. The value of these stock options has been estimated at $2,378 (2017 - $425), which is a weighted average grant date value per option of $3.84 (2017 - $1.60), using the Black-Scholes valuation model and the following weighted average assumptions: 2018 2017 Risk-free interest rate 2.02% 2.70% Expected volatility 77% 98% Expected life (years) 4.2 4.4 Forfeiture rate 5% 4% Option activity for the year ended December 31, 2018 and 2017 was as follows: 2018 2017 Weighted Weighted average average Number exercise price Number exercise price $ $ Outstanding - Beginning of year 1,498,052 2.26 1,961,791 2.23 Granted 619,505 6.65 266,814 2.40 Exercised (626,875 ) 1 2.18 (627,256 ) 1 2.21 Expired (5,569 ) 1.80 (64,068 ) 2.19 Forfeited (10,636 ) 4.92 (39,229 ) 2.37 Outstanding - End of year 1,474,477 4.12 1,498,052 2.26 1 Of the 626,875 (2017 - 627,256) options exercised, 443,748 (2017 - 548,833) elected the cashless exercise, under which 297,626 shares (2017 - 238,130) were issued. These options would have otherwise been exercisable for proceeds of $975 (2017 - $1,227) on the exercise date. The weighted average exercise price of options exercisable at December 31, 2018 is $4.09 (2017 - $2.25). The maximum number of common shares issuable under the Corporation’s stock option plan shall not exceed 3,437,500, inclusive of all shares presently reserved for issuance pursuant to previously granted stock options. At December 31, 2018, the following options were outstanding: Options outstanding Options exercisable Weighted Weighted Weighted average Weighted average Exercise average remaining average remaining price exercise contractual life exercise contractual life range Number price (years) Number price (years) $ $ $ 1.98 – 285,939 2.08 2.16 285,939 2.08 2.16 2.30 – 259,377 2.37 1.48 259,377 2.37 1.48 2.39 – 310,125 2.50 2.63 310,125 2.50 2.63 3.02 – 400,625 6.36 4.17 5,312 3.20 0.25 6.73 – 218,411 7.09 4.17 – – – 1,474,477 4.12 2.98 860,753 2.33 2.11

Warrants

Warrants	12 Months Ended
	Dec. 31, 2018
Disclosure of warrants [Abstract]
Warrants	14 Warrants Warrant activity for the years ended December 31, 2018 and 2017 was as follows: 2018 2017 Weighted Weighted average average exercise exercise Number price Amount Number price Amount $ $ $ $ Opening balance 2,087,598 2.46 674 2,725,596 2.27 660 Granted 134,766 6.53 332 144,231 4.22 208 Exercised (2,029,905 ) 2.41 (591 ) (782,229 ) 2.18 (194 ) Closing balance 192,459 415 2,087,598 674 The fair values of warrants are estimated using the Black-Scholes option pricing model. The weighted average grant date value per warrant of warrants issued in 2018 was $2.47 (2017 - $1.44), determined using the Black-Scholes valuation model and the following weighted average assumptions: 2018 2017 Risk-free interest rate 1.84% 2.70% Expected volatility 68% 72% Expected dividend yield – – Expected life (years) 2 2

Deferred income taxes

Deferred income taxes	12 Months Ended
	Dec. 31, 2018
Major components of tax expense (income) [abstract]
Deferred income taxes	15 Deferred income taxes a) Reconciliation of total tax recovery The effective rate on the Corporation’s loss before income tax differs from the expected amount that would arise using the statutory income tax rates. A reconciliation of the difference is as follows: 2018 2017 $ $ Loss before income taxes (21,935 ) (12,027 ) Income tax rate 30.0 % 31.0 % (6,581 ) (3,728 ) Effect on income taxes of: Non-deductible share-based compensation 507 533 Unrecognized deductible temporary difference and carry forward amounts and experimental development expenditures 6,040 3,184 Other non-deductible items 34 11 Income tax recovery – – b) Deferred income tax The significant components of the Corporation’s deferred income tax are as follows: 2018 2017 $ $ Deferred income tax liabilities: Intangibles – – Deferred income tax assets: Non-capital losses – – Net deferred income tax liability – – The following reflects the balance of temporary differences for which no deferred income tax asset has been recognized: 2018 2017 $ $ Non-capital losses 63,230 43,719 Scientific research and experimental development expenditures 20,096 13,906 Non-refundable investment tax credits 3,832 2,801 Deductible share issuance costs 2,028 1,846 Long-term debt 7,612 6,243 Property and equipment 725 1,144 c) Non-capital losses As at December 31, 2018, the Corporation had approximately $63,230 in losses available to reduce future taxable income. The benefit of these losses has not been recorded in the accounts as realization is not considered probable. These losses may be claimed no later than: $ For the year ending December 31, 2025 1,000 2026 1,100 2027 1,470 2028 1,770 2029 660 2030 2,640 2031 5,180 2032 4,110 2033 4,270 2034 3,400 2035 7,560 2036 5,100 2037 6,700 2038 18,270 63,230 d) Scientific research and experimental development expenditures The Corporation has approximately $20,096 of unclaimed scientific research and development expenditures, which may be carried forward indefinitely and used to reduce taxable income in future years. The potential income tax benefits associated with the unclaimed scientific research and experimental development expenditures have not been recognized in the accounts as realization is not considered probable. e) Non-refundable investment tax credits The Corporation also has approximately $3,832 in non-refundable federal investment tax credits which may be carried forward to reduce taxes payable. These tax credits will be fully expired by 2038. The benefit of these tax credits has not been recorded in the accounts as realization is not considered probable.

Capital management

Capital management	12 Months Ended
	Dec. 31, 2018
Disclosure of capital management [Abstract]
Capital management	16 Capital management The Corporation views capital as the sum of its cash and cash equivalents, long-term debt and equity. The Corporations’ objectives when managing capital is to safeguard its ability to continue as a going concern in order to provide an adequate return to shareholders and maintain a sufficient level of funds to finance its research and development activities, general and administrative expenses, working capital and overall capital expenditures, including those associated with patents and trademarks. To maintain or adjust the capital structure, the Corporation may attempt to issue new shares, issue new debt, acquire or dispose of assets, all of which are subject to market conditions and the terms of the underlying third party agreements. The Corporation is not subject to any regulatory capital requirements imposed. 2018 2017 $ $ Total long-term debt 8,150 6,537 Less: Cash and cash equivalents (14,895 ) (14,909 ) Net debt (6,745 ) (8,372 ) Equity 4,317 6,343 Total capital (2,428 ) (2,029 ) The Corporation is in compliance with its debt covenants.

Financial instruments

Financial instruments	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
Financial instruments	17 Financial instruments Fair value of financial instruments Financial instruments are defined as a contractual right or obligation to receive or deliver cash on another financial asset. The following table sets out the approximate fair values of financial instruments as at the consolidated statements of financial position date with relevant comparatives: 2018 2017 Carrying Carrying value Fair value value Fair value $ $ $ $ Cash and cash equivalents 14,895 14,895 14,909 14,909 Amounts receivable 780 780 110 110 Accounts payable and accrued liabilities 7,557 7,557 2,741 2,741 Amounts due to directors 49 49 21 21 Long-term debt 8,150 8,150 6,537 6,537 Assets and liabilities, such as commodity taxes, that are not contractual and that arise as a result of statutory requirements imposed by governments, do not meet the definition of financial assets or financial liabilities and are, therefore, excluded from amounts receivable and accounts payable. Fair value of items, which are short-term in nature, have been deemed to approximate their carrying value. The above noted fair values, presented for information only, reflect conditions that existed only at December 31, 2018, and do not necessarily reflect future value or amounts which the Corporation might receive if it were to sell some or all of its assets to a willing buyer in a free and open market. The fair value of the long-term debt is estimated based on the expected interest rates for similar borrowings by the Corporation at the consolidated statements of financial position dates. At December 31, 2018, the fair value is estimated to be equal to the carrying amount. Risk management The Corporation, through its financial assets and liabilities, has exposure to the following risks from its use of financial instruments: interest rate risk; credit risk; liquidity risk; and currency risk. Management is responsible for setting acceptable levels of risk and reviewing risk management activities as necessary. a) Interest rate risk The Corporation has limited exposure to interest rate risk on its lending and borrowing activities. The Corporation has a significant loan in which the interest rate is dependent on the cost of funds from the lender plus 1%. This interest rate is fixed at the time that each loan disbursement is made, resulting in limited variability to the interest rate. The total amount drawn down on the loan as at December 31, 2018 is $5,000 (2017 - $5,000) and the Corporation is required to make interest payments in fiscal 2019 of $148. The Corporation has an interest-free loan that is repayable over 84 months, resulting in required principal debt payments in fiscal 2019 of $67, and also has a loan which has a fixed interest rate of 8% per annum resulting in interest payments in 2019 of $21. The remaining outstanding debt as at December 31, 2018 is interest-free, only becoming repayable when revenues are earned. The Corporation is required to make principal debt payments in fiscal 2019 of $5. b) Credit risk Credit risk arises from cash and cash equivalents and amounts receivable. The Corporation invests excess cash in high-interest savings accounts or in highly liquid temporary investments of Schedule 1 Canadian Banks. The credit risk of cash and cash equivalents is limited because the counter-parties are banks with high credit ratings assigned by international credit rating agencies. The total of amounts receivable disclosed in the consolidated statements of financial position as at December 31, 2018 of $1,337 (2017 - $261) is comprised mainly of current period advances due to the Corporation for government assistance programs and cost-recoveries from third party partners, as well as sales taxes recoverable. If required, the balance is shown net of allowances for bad debts, estimated by management based on prior experience and their assessment of the current economic environment. Historically, there have been no collection issues and the Corporation does not believe it is subject to any significant concentration of credit risk. c) Liquidity risk Liquidity risk represents the possibility that the Corporation may not be able to gather sufficient cash resources when required and under reasonable conditions to meet its financial obligations. Since the Corporation’s inception, operations have been financed through the sale of shares, issuance of debt, revenue and cost-recoveries from license agreements, interest income on funds available for investment, government assistance and income tax credits. The Corporation has incurred significant operating losses and negative cash flows from operations since inception and has an accumulated deficit of $92,754 as at December 31, 2018. While the Corporation has $14,895 in cash and cash equivalents at December 31, 2018, it continues to have an ongoing need for substantial capital resources to research and develop, commercialize and manufacture its products and technologies. The Corporation is currently not yet receiving a significant ongoing revenue stream from its license agreements, nor can it be certain that it will receive significant revenue from these agreements before additional cash is required. As a result, there can be no assurance that the Corporation will have sufficient capital to fund its ongoing operations, and develop or commercialize any of its products without future financing. The following table outlines the contractual maturities for long-term debt repayable based on a percentage of revenues for the Corporation’s financial liabilities. The long-term debt is comprised of the contributions received described in note 11, less amounts that have been repaid as at December 31, 2018: Total Year 1 Years 2 to 3 Years 4 to 5 After 5 years $ $ $ $ $ Accounts payable and accrued liabilities 7,575 7,575 – – – Amounts due to directors 49 49 – – – Short term and low value leases 66 18 27 21 Long-term leases 2,398 275 533 518 1,072 Long-term debt 15,612 264 5,324 142 9,882 25,700 8,181 5,884 681 10,954 The above amounts include interest payments, where applicable. d) Currency risk The Corporation incurs some revenue and expenses in U.S. dollars and, as such, is subject to fluctuations as a result of foreign exchange rate variation. The Corporation does not have in place any tools to manage its foreign exchange risk, as these U.S. dollars transactions are not significant to overall operations. Foreign exchange loss of $139 for the year ended December 31, 2018 (2017, foreign exchange gain - $10) are included in general and administrative expenses. If the foreign exchange had been 1% higher/lower, with all other variables held constant, it would have had an immaterial impact on the foreign exchange gain/loss.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2018
Disclosure of contingent liabilities [abstract]
Commitments	18 Commitments The minimum annual payments under long-term lease agreements for office premises and equipment expiring over the next five years are as follows: $ Year ending December 31, 2019 257 2020 253 2021 253 2022 251 2023 247 On July 12, 2010, the Corporation entered into a License Agreement with Merck KGaA to in-license EMD 640744, an investigational therapeutic Survivin-based cancer antigen designed to target multiple solid tumors and hematological malignancies. Should the Corporation’s research using these antigens continue and prove successful through clinical trials and on to commercialization, the Corporation would be required to pay certain future milestones and royalty payments along the way. The likelihood and timing of these payments is not known at this time.

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2018
Disclosure of transactions between related parties [abstract]
Related party transactions	19 Related party transactions During the year ended December 31, 2018, there were no related party transactions (2017 - $nil).

Expenses by nature

Expenses by nature	12 Months Ended
	Dec. 31, 2018
Expenses
Expenses by nature	20 Expenses by nature 2018 2017 $ $ Salaries, wages and benefits 5,945 4,025 Other research and development expenditures, including clinical costs 8,398 3,045 Professional and consulting fees 1,987 1,231 Travel 550 225 Office, rent and telecommunications 586 414 Insurance 444 81 Marketing, communications and investor relations 1,370 1,154 Depreciation 325 140 Stock-based compensation 1,182 571 Deferred share unit compensation 508 1,147 Other 800 329 Accreted interest 1,385 966 Research and development tax credits (1,027 ) (537 ) Government assistance (35 ) (542 ) 22,418 12,249

Compensation of key management

Compensation of key management	12 Months Ended
	Dec. 31, 2018
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
Compensation of key management	21 Compensation of key management Key management includes the Corporation’s Directors, the Chief Executive Officer, the Chief Financial Officer, and the Chief Medical Officer. Compensation awarded to key management is summarized as follows: 2018 2017 $ $ Salaries and other benefits 1,651 1,329 Stock-based compensation 2,121 792 3,772 2,121

Share consolidation

Share consolidation	12 Months Ended
	Dec. 31, 2018
Disclosure of share consolidation [Abstract]
Share consolidation	22 Share consolidation On May 2, 2018, the Corporation completed a share consolidation on the basis of one new common share for every 3.2 currently outstanding shares. Effective at the opening of trading on May 10, 2018, the Corporation’s common shares commenced trading on a consolidated basis.

Subsequent event

Subsequent event	12 Months Ended
	Dec. 31, 2018
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent event	23 Subsequent event On March 6, 2019, the Corporation completed the March 2019 Public Offering, issuing an aggregate of 4,900,000 common shares at a price of $5.45 per common share, raising gross proceeds of $26.7 million. On March 11, 2019, the underwriters partially exercised their option to purchase common shares, resulting in the issuance of 504,855 common shares of the Corporation at a price of $5.45 per share for additional gross proceeds of approximately $2.75 million. As a result of the exercise of this option, the Corporation has raised total gross proceeds of approximately $29.46 million before deducting the underwriting commissions and offering expenses, which are estimated to be $2 million.

Significant accounting polici_2

Significant accounting policies, judgments and estimation uncertainty (Policies)	12 Months Ended
	Dec. 31, 2018
Disclosure of significant accounting policies, judgments and estimation uncertainty [Abstract]
Basis of measurement	Basis of measurement The consolidated financial statements have been prepared under the historical cost convention.
Consolidation	Consolidation The financial statements of the Corporation consolidate the accounts of IMV Inc. and its subsidiary. All intercompany transactions, balances and unrealized gains and losses from intercompany transactions are eliminated on consolidation. There are no non-controlling interests, therefore, all loss and comprehensive loss is attributable to the shareholders of the Corporation.
Foreign currency translation	Foreign currency translation i) Functional and presentation currency Items included in the consolidated financial statements of the Corporation are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The consolidated financial statements are presented in Canadian dollars, which is the Corporation’s functional currency. ii) Transactions and balances Foreign currency translation of monetary assets and liabilities, denominated in currencies other than the Corporation’s functional currency, are converted at the rate of exchange in effect at the consolidated statement of financial position date. Income and expense items are translated at the rate of exchange in effect at the transaction date. Translation gains or losses are included in determining income or loss for the year. Foreign exchange loss of $139 of for the year ended December 31, 2018 (2017 - $10 gain) is included in general and administrative expenses.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents include cash on hand, balances with banks, and highly liquid temporary investments that are readily convertible to known amounts of cash.
Financial instruments	Financial instruments Financial assets and liabilities are recognized when the Corporation becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Corporation has transferred substantially all risks and rewards of ownership. Financial assets and liabilities are offset and the net amount is reported in the consolidated statement of financial position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously. The Corporation recognizes financial instruments based on their classification. Depending on the financial instruments’ classification, changes in subsequent measurements are recognized in net loss and comprehensive loss. The Corporation has implemented the following classifications: Cash and cash equivalents and amounts receivable are classified as amortized cost (previously loans and receivables). After their initial fair value measurement, they are measured at amortized cost using the effective interest method; and Accounts payable and accrued liabilities, amounts due to directors and long-term debt are classified as other amortized cost (previously financial liabilities). After their initial fair value measurement, they are measured at amortized cost using the effective interest method.
Impairment of financial assets	Impairment of financial assets The Corporation applies the simplified method of the expected credit loss model required under IFRS 9. Under this method, the Corporation estimates a lifetime expected loss allowance for all receivables. Receivables are written off when there is no reasonable expectation of recovery. If there is objective evidence that an impairment loss has been incurred, the amount of the loss is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows. The present value of the estimated future cash flows is discounted at the financial asset’s original effective interest rate.
Property and equipment	Property and equipment Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Corporation and the cost can be measured reliably. The carrying amount of a replaced asset is derecognized when replaced. Repairs and maintenance costs are charged to the consolidated statement of loss and comprehensive loss during the year in which they are incurred. Depreciation of property and equipment is calculated using the declining-balance method at the following annual rates: Computer equipment 30% Computer software 100% Furniture and fixtures 20% Laboratory equipment 20% Leasehold improvements and leased premises straight-line Residual values, method of depreciation and useful lives of the assets are reviewed annually and adjusted if appropriate. Gains and losses on disposals of property and equipment are determined by comparing the proceeds with the carrying amount of the asset and are included as part of general and administrative expenses in the consolidated statement of loss and comprehensive loss. Property and equipment and intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of measuring recoverable amounts, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units or CGUs). The recoverable amount is the higher of an asset’s fair value less the costs to sell, and value in use (being the present value of the expected future cash flows of the relevant asset or CGU). An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The Corporation evaluates impairment losses for potential reversals when events or circumstances warrant such consideration.
Income tax	Income tax Income tax is comprised of current and deferred income tax. Income tax is recognized in the consolidated statement of loss and comprehensive loss except to the extent that it relates to items recognized directly in equity, in which case the income tax is also recognized directly in equity. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted, at the end of the reporting period, and any adjustment to tax payable in respect of previous years. In general, deferred income tax is recognized in respect of temporary differences including non-refundable investment tax credits, arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined on a non-discounted basis using tax rates and laws that have been enacted or substantively enacted at the consolidated statement of financial position date and are expected to apply when the deferred income tax asset or liability is settled. Deferred income tax assets are recognized to the extent that it is probable that the assets can be recovered. Deferred income tax is provided on temporary differences arising on investments in subsidiaries and associates, except in the case of subsidiaries, where the timing of the reversal of the temporary difference is controlled by the Corporation and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred income tax assets and liabilities are presented as non-current.
Research and development	Research and development All research costs are expensed in the period incurred. Development costs are expensed in the period incurred, unless they meet the criteria for capitalization, in which case, they are capitalized and then amortized over the useful life. Development costs are written off when there is no longer an expectation of future benefits.
Revenue recognition	Revenue recognition Revenues are recognized as the Corporation satisfies its performance obligations under the terms of the contract. Performance obligations are considered to be satisfied when the customer obtains control of the related asset. Current and expected future revenue streams include: (i) milestone payments generated upon entering into potential contractual partnerships and achieving development and sales milestones; (ii) future royalties generated from the eventual commercialization of the Corporation’s products; and (iii) amounts generated for providing formulation and research support services related to existing licensing and research agreements with partners. Revenue resulting from formulation services is recognized in the accounting period in which the formulation is delivered to the customer. Typically, the customer does not have control of the asset while services are being performed and, therefore, revenues are recognized at the time the Corporation has completed its obligation and the customer obtains control of the asset. Revenue resulting from research support services is recognized over time as the services are performed, as the customer benefits simultaneously from the service as the Corporation satisfies its performance obligation. The Corporation expects to generate upfront payments, milestone and royalty revenues from future licenses for the Corporation’s products. Upfront payments and milestones will be recognized as revenue when or as the underlying obligations are achieved and are not conditional on any further performance, which could be at a point in time or over time depending on the contractual terms. Royalty revenue will be recognized in the period in which the Corporation earns the royalty. The Corporation does not generate licensing or royalty revenues at this time.
Share capital	Share capital Common shares are classified as equity. Incremental costs directly attributable to the issuance of shares are recognized as a deduction from share capital.
Loss per share	Loss per share Basic loss per share (“LPS”) is calculated by dividing the net loss for the year attributable to equity owners of the Corporation by the weighted average number of common shares outstanding during the year. Diluted LPS is calculated by adjusting the weighted average number of common shares outstanding for dilutive instruments. The number of shares included with respect to options, warrants and similar instruments is computed using the treasury stock method. Diluted LPS is equal to the LPS as the Corporation is in a loss position and all securities, comprised of options and warrants, would be anti-dilutive.
Stock-based compensation plan	Stock-based compensation plan The Corporation grants stock options to certain employees and non-employees. Starting January 1, 2018, stock options vest over three years (33 1/3% per year) and expire after five years. Each tranche in an award is considered a separate award with its own vesting period and grant date fair value. Fair value of each tranche is measured at the date of grant using the Black-Scholes option pricing model. Compensation expense is recognized over the tranche’s vesting period by increasing contributed surplus based on the number of awards expected to vest. The number of awards expected to vest is reviewed at least annually, with any impact being recognized immediately. A holder of an option may, rather than exercise such option, elect a cashless exercise of such option payable in common shares equaling the amount by which the value of an underlying share at that time exceeds the exercise price of such option or warrant to acquire such share.
Deferred share unit plan	Deferred share unit plan The Corporation grants deferred share units (“DSUs”) to members of its Board of Directors, who are not employees or officers of the Corporation. All DSUs awarded vest immediately and cannot be redeemed until the holder is no longer a director of the Corporation. All services received in exchange for the grant of DSUs are measured at their fair values. The redemption value of a DSU will be based on the market value of the Corporation’s common shares at the time of redemption. On an ongoing basis, the Corporation values its liability with respect to DSUs at the current market value of a corresponding number of common shares and records any increase or decrease in the DSU obligation. Compensation expense is recognized at each grant date in general and administrative expenses on the consolidated statement of loss and comprehensive loss.
Government assistance	Government assistance Government assistance consists of non-repayable government grants, from a number of government agencies and the difference between the fair value and the book value of repayable low-interest government loans, recorded initially at fair value. Government assistance is recorded in the period earned using the cost reduction method and is included in government assistance on the consolidated statement of loss and comprehensive loss. At December 31, 2018, $7 (2017 - $10) of government assistance is included in amounts receivable.
Research and development tax credits	Research and development tax credits Refundable investment tax credits relating to scientific research and experimental development expenditures are recorded in the accounts in the fiscal period in which the qualifying expenditures are incurred provided there is reasonable assurance that the tax credits will be realized. Refundable investment tax credits, in connection with research and development activities, are accounted for using the cost reduction method and included in government assistance on the statement of loss and comprehensive loss. Amounts recorded for refundable investment tax credits are calculated based on the expected eligibility and tax treatment of qualifying scientific research and experimental development expenditures recorded in the Corporation’s consolidated financial statements.
Critical accounting estimates and judgments	Critical accounting estimates and judgments The Corporation makes estimates and assumptions concerning the future that will, by definition, seldom equal actual results. The following are the estimates and judgments applied by management that most significantly affect the Corporation’s consolidated financial statements. The following estimates and judgments have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. Calculation of initial fair value and carrying amount of long-term debt Atlantic Innovation Fund (“AIF”) loans The initial fair value of the AIF loans is determined by using a discounted cash flow analysis for each of the loans, which require a number of assumptions. The difference between the face value and the initial fair value of the AIF loans is recorded in the consolidated statement of loss and comprehensive loss as government assistance. The carrying amount of the AIF loans requires management to adjust the long-term debt to reflect actual and revised estimated cash flows whenever revised cash flow estimates are made or new information related to market conditions is made available. Management recalculates the carrying amount by computing the present value of the estimated future cash flows at the original effective interest rate. Any adjustments are recognized in the consolidated statement of loss as accreted interest after initial recognition. The significant assumptions used in determining the discounted cash flows include estimating the amount and timing of future revenue for the Corporation and the discount rate. As the AIF loans are repayable based on a percentage of gross revenue, if any, the determination of the amount and timing of future revenue significantly impacts the initial fair value of the loan, as well as the carrying value of the AIF loans at each reporting date. The expected revenue streams include i) estimated royalties generated from the eventual commercialization of the Corporation’s products, and ii) estimated milestone payments generated upon entering into potential contractual partnerships and achieving development and sales milestones. The amount and timing of estimated milestone payments forecasted are earlier and less predictable, therefore, changes in the amount and timing of milestone payments could have a significant impact on the fair value of the loans. Further, the Corporation is in the early stages of research for its product candidates; accordingly, determination of the amount and timing of any revenue streams requires significant judgment by management. The discount rate determined on initial recognition of the AIF loans is used to determine the present value of estimated future cash flows expected to be required to settle the debt. In determining the appropriate discount rates, the Corporation considered the interest rates of similar long-term debt arrangements with similar terms. The AIF loans are repayable based on a percentage of gross revenue, if any; accordingly, finding financing arrangements with similar terms is difficult and management was required to use significant judgment in determining the appropriate discount rates. Management used a discount rate of 35% to discount the AIF loans. If the weighted average discount rate used in determining the initial fair value and the carrying value at each reporting date of all AIF loans, with repayment terms based on future revenue, had been determined to be higher by 10%, or lower by 10%, the carrying value of the long-term debt at December 31, 2018 would have been an estimated $728 lower or $1,036 higher, respectively. A 10% increase or decrease in the total forecasted revenue would not have a significant impact on the amount recorded for the loans. If the total forecasted revenue were reduced to $nil, no amounts would be forecast to be repaid on the AIF loans, and the AIF loans payable at December 31, 2018 would be recorded at $nil, which would be a reduction in the AIF loans payable of $3,193. If the timing of the receipt of forecasted future revenue was delayed by two years, the carrying value of the long-term debt at December 31, 2018 would have been an estimated $1,440 lower. Province of Nova Scotia (“The Province”) The initial fair value of the Province loan is determined by using a discounted cash flow analysis for the loan. The interest rate on the loan is below the market rate for a commercial loan with similar terms. The significant assumption used in determining the discounted cash flows is the discount rate. Any changes in the discount rate would impact the amount recorded as initial fair value of the long-term debt and the carrying value of the long-term debt at each reporting date. In determining the appropriate discount rate, the Corporation considers the interest rates of similar long-term debt arrangements with similar terms. The Province loan is a government loan with principal payments only required at the end of seven years; accordingly, finding financing arrangements with similar terms is difficult and management was required to use significant judgment in determining the appropriate discount rates. Management used a discount rate of 11% to discount the Province loan. If the discount rate used for the Province loan had been determined to be higher or lower by 5% (resulting in discount rates of 16% or 6%, respectively), the carrying value of the long-term debt at December 31, 2018 would have been an estimated $325 lower or $353 higher, respectively. The difference between the book value and the initial fair value of the Province loan is recorded in the consolidated statement of loss as government assistance on initial recognition. Any changes in the amounts recorded on the consolidated statement of financial position for the Province loan result in an offsetting charge to accreted interest after initial recognition in the consolidated statement of loss.

New standards and interpretat_2

New standards and interpretations adopted January 1, 2018 (Tables)	12 Months Ended
	Dec. 31, 2018
New Standards And Interpretations Adopted January 1 2018 Schedule Of Operating Lease Commitment
Schedule of Operating Lease Commitment	$ Operating lease commitment as at December 31, 2017 1 275 Recognition exemption for: Short-term leases (131 ) Leases of low value assets (14 ) Commitments attributable to non-lease components (65 ) Extension option reasonably certain to be recognized 2 51 116 Discounted using the incremental borrowing rate at January 1, 2018 (29 ) Lease liability recognized at January 1, 2018 87 1 Does not include $2,262 related to new office space for which the lease commencement date was June 1, 2018. 2

Significant accounting polici_3

Significant accounting policies, judgments and estimation uncertainty (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of significant accounting policies, judgments and estimation uncertainty [Abstract]
Schedule of Depreciation of Property and Equipment Annual Rates	Depreciation of property and equipment is calculated using the declining-balance method at the following annual rates: Computer equipment 30% Computer software 100% Furniture and fixtures 20% Laboratory equipment 20% Leasehold improvements and leased premises straight-line

Amounts receivable (Tables)

Amounts receivable (Tables)	12 Months Ended
	Dec. 31, 2018
Trade and other current receivables [abstract]
Schedule of Amounts Receivable	2018 2017 $ $ Amounts due from government assistance and government loans 7 10 Sales tax receivable 557 151 Revenue from subcontracts 33 10 Other 740 90 1,337 261

Property and equipment (Tables)

Property and equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of Property and Equipment	Computer equipment Leasehold and Furniture Laboratory Leased improve- software and fixtures equipment Premises ments Total $ $ $ $ $ $ Year ended December 31, 2017 Opening net book value 43 17 256 – – 316 Additions 73 15 282 – 17 387 Disposals Cost (9 ) – – – – (9 ) Accumulated depreciation 9 – – – – 9 Depreciation for the year (50 ) (5 ) (79 ) – (6 ) (140 ) Closing net book value 66 27 459 – 11 563 At December 31, 2017 Cost 205 85 1,166 – 17 1,473 Accumulated depreciation (139 ) (58 ) (707 ) – (6 ) (910 ) Net book value 66 27 459 – 11 563 Year ended December 31, 2018 Opening net book value 66 27 459 – 11 563 Additions 79 171 217 1,417 782 2,666 Disposals Cost (9 ) (61 ) (37 ) – – (107 ) Accumulated depreciation 7 47 31 – – 85 Depreciation for the year (47 ) (21 ) (112 ) (94 ) (50 ) (325 ) – – – Closing net book value 96 163 558 1,323 743 2,883 At December 31, 2018 Cost 275 194 1,346 1,417 800 4,032 Accumulated depreciation (179 ) (31 ) (788 ) (94 ) (57 ) (1,149 ) Net book value 96 163 558 1,323 743 2,883

Accounts payable and accrued _2

Accounts payable and accrued liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Trade and other current payables [abstract]
Schedule of Accounts Payable and Accrued Liabilities	2018 2017 $ $ Trade payables 5,282 1,683 Accrued liabilities 2,275 1,057 Payroll taxes 18 20 7,575 2,760

Lease obligation (Tables)

Lease obligation (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of finance lease and operating lease by lessee [abstract]
Schedule of Lease Obligation	Amount $ Balance – December 31, 2017 – Leases recognized upon transition to IFRS 16 87 Additions 1,291 Repayment of lease obligation (74 ) Accreted interest 94 Balance – December 31, 2018 1,398 Less: Current portion (90 ) Non-current portion 1,308

Deferred share units (DSUs) (Ta

Deferred share units (DSUs) (Tables)	12 Months Ended
	Dec. 31, 2018
Deferred Share Units Dsus Schedule Of Deferred Share Units
Schedule of Deferred Share Units	DSU activity for the year ended December 31, 2018 and the year ended December 31, 2017 are as follows: December 31, December 31, 2018 2017 Number Number Opening balance 186,330 101,563 Granted 97,072 84,767 Redeemed (59,798 ) – Closing balance 223,604 186,330

Long-term debt (Tables)

Long-term debt (Tables)	12 Months Ended
	Dec. 31, 2018
Borrowings [abstract]
Schedule of Long-term debt	2018 2017 $ $ Atlantic Canada Opportunities Agency (“ACOA”) Atlantic Innovation Fund interest-free loan with a maximum contribution of $3,786. Annual repayments, commencing December 1, 2008, are calculated as a percentage of gross revenue for the preceding fiscal year, at 2% when gross revenues are less than $5,000 and 5% when gross revenues are greater than $5,000. As at December 31, 2018, the amount drawn down on the loan, net of repayments, is $3,744 (2017 - $3,747). 1,202 758 ACOA Atlantic Innovation Fund interest-free loan with a maximum contribution of $3,000. Annual repayments, commencing December 1, 2011, are calculated as a percentage of gross revenue for the preceding fiscal year, at 2% when gross revenues are less than $5,000 and 5% when gross revenues are greater than $5,000. As at December 31, 2018, the amount drawn down on the loan is $2,995 (2017 - $2,997). 1,034 651 ACOA Business Development Program, interest-free loan with a maximum contribution of $395, repayable in monthly payments beginning October 2015 of $3 until October 2017 and $6 until September 2022. As at December 31, 2018, the amount drawn down on the loan, net of repayments, is $251 (2017 - $318). 238 294 ACOA Atlantic Innovation Fund interest-free loan with a maximum contribution of $2,944, annual repayments commencing September 1, 2014, are calculated as a percentage of gross revenue from specific product(s) for the preceding fiscal year, at 5% for the first 5 year period and 10%, thereafter. As at December 31, 2018, the amount drawn down on the loan is $2,944 (2017 - $2,944). 957 733 TNC 120-140 Eileen Stubbs Ltd. (the “Landlord”) loan, with a maximum contribution of $300,000, bearing interest a t 8% annum, is repayable in monthly payments beginning upon receipt of the final installment of the loan until May 31, 2028. The loan is made available in three equal installments based on the Corporation meeting certain milestones. As at December 31, 2018, the amount drawn down on the loan is $300 (2017 - $ nil). 300 – Province of Nova Scotia “The Province” secured loan with a maximum contribution of $5,000, interest bearing at a rate equal to the Province’s cost of funds plus 1%, compounded semi-annually and payable monthly. The loan is made available in four equal installments based on the Corporation meeting certain milestones, and is repayable on the seventh anniversary date of the first disbursement. The Corporation and its subsidiary have provided a general security agreement granting a first security interest in favour of the Province of Nova Scotia in and to all the assets of the Corporation and its subsidiary, including the intellectual property. As at December 31, 2018, the amount drawn down on the loan is $5,000 (2017 - $5,000). 4,419 4,101 8,150 6,537 Less: Current portion 81 61 8,069 6,476
Schedule of Repayments of Long-term debt	The minimum annual principal repayments of long-term debt over the next five years, excluding the Atlantic Innovation Fund repayments for 2019 and beyond which are not determinable at this time, are as follows: $ Year ending December 31, 2019 81 2020 4,286 2021 90 2022 78 2023 31 2018 2017 $ $ Balance – Beginning of year 6,537 6,149 Borrowings, net of $nil (2017 - $nil) allocated to government assistance 300 – Accreted interest 1,385 966 Revaluation of long-term debt – (506 ) Repayment of debt (72 ) (72 ) Balance – End of year 8,150 6,537 Less: Current portion 81 61 Non-current portion 8,069 6,476

Share capital (Tables)

Share capital (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of classes of share capital [abstract]
Schedule of Share Capital	Unlimited number of common shares and preferred shares, issuable in series, all without par value. Number of common shares Amount $ Issued and outstanding Balance – December 31, 2016 36,817,328 58,154 Issued for cash consideration, net of issuance costs 2,403,846 8,803 Stock options exercised 316,538 1,265 Warrants exercised 782,229 1,891 Balance – December 31, 2017 40,319,941 70,113 Issued for cash, net of issuance costs 2,246,094 12,895 Stock options exercised 480,754 1,444 DSUs redeemed 29,713 220 Warrants exercised 2,029,899 5,480 Balance – December 31, 2018 45,106,401 90,152

Contributed surplus (Tables)

Contributed surplus (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Schedule of Contributed Surplus	Amount $ Contributed surplus Balance – December 31, 2016 6,961 Share-based compensation – stock options vested 571 Warrants expired – Stock options exercised (1,157 ) Balance – December 31, 2017 6,375 Share-based compensation – stock options vested 1,182 Stock options exercised (1,053 ) Balance – December 31, 2018 6,504
Schedule of Weighted Average Assumptions	2018 2017 Risk-free interest rate 2.02% 2.70% Expected volatility 77% 98% Expected life (years) 4.2 4.4 Forfeiture rate 5% 4%
Schedule of Option Activity	Option activity for the year ended December 31, 2018 and 2017 was as follows: 2018 2017 Weighted Weighted average average Number exercise price Number exercise price $ $ Outstanding - Beginning of year 1,498,052 2.26 1,961,791 2.23 Granted 619,505 6.65 266,814 2.40 Exercised (626,875 ) 1 2.18 (627,256 ) 1 2.21 Expired (5,569 ) 1.80 (64,068 ) 2.19 Forfeited (10,636 ) 4.92 (39,229 ) 2.37 Outstanding - End of year 1,474,477 4.12 1,498,052 2.26 1 Of the 626,875 (2017 - 627,256) options exercised, 443,748 (2017 - 548,833) elected the cashless exercise, under which 297,626 shares (2017 - 238,130) were issued. These options would have otherwise been exercisable for proceeds of $975 (2017 - $1,227) on the exercise date.
Schedule of Options Outstanding	At December 31, 2018, the following options were outstanding: Options outstanding Options exercisable Weighted Weighted Weighted average Weighted average Exercise average remaining average remaining price exercise contractual life exercise contractual life range Number price (years) Number price (years) $ $ $ 1.98 – 285,939 2.08 2.16 285,939 2.08 2.16 2.30 – 259,377 2.37 1.48 259,377 2.37 1.48 2.39 – 310,125 2.50 2.63 310,125 2.50 2.63 3.02 – 400,625 6.36 4.17 5,312 3.20 0.25 6.73 – 218,411 7.09 4.17 – – – 1,474,477 4.12 2.98 860,753 2.33 2.11

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of Warrant Activity	Option activity for the year ended December 31, 2018 and 2017 was as follows: 2018 2017 Weighted Weighted average average Number exercise price Number exercise price $ $ Outstanding - Beginning of year 1,498,052 2.26 1,961,791 2.23 Granted 619,505 6.65 266,814 2.40 Exercised (626,875 ) 1 2.18 (627,256 ) 1 2.21 Expired (5,569 ) 1.80 (64,068 ) 2.19 Forfeited (10,636 ) 4.92 (39,229 ) 2.37 Outstanding - End of year 1,474,477 4.12 1,498,052 2.26 1 Of the 626,875 (2017 - 627,256) options exercised, 443,748 (2017 - 548,833) elected the cashless exercise, under which 297,626 shares (2017 - 238,130) were issued. These options would have otherwise been exercisable for proceeds of $975 (2017 - $1,227) on the exercise date.
Schedule of Weighted Average Assumptions	2018 2017 Risk-free interest rate 2.02% 2.70% Expected volatility 77% 98% Expected life (years) 4.2 4.4 Forfeiture rate 5% 4%
Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Schedule of Warrant Activity	Warrant activity for the years ended December 31, 2018 and 2017 was as follows: 2018 2017 Weighted Weighted average average exercise exercise Number price Amount Number price Amount $ $ $ $ Opening balance 2,087,598 2.46 674 2,725,596 2.27 660 Granted 134,766 6.53 332 144,231 4.22 208 Exercised (2,029,905 ) 2.41 (591 ) (782,229 ) 2.18 (194 ) Closing balance 192,459 415 2,087,598 674
Schedule of Weighted Average Assumptions	The weighted average grant date value per warrant of warrants issued in 2018 was $2.47 (2017 - $1.44), determined using the Black-Scholes valuation model and the following weighted average assumptions: 2018 2017 Risk-free interest rate 1.84% 2.70% Expected volatility 68% 72% Expected dividend yield – – Expected life (years) 2 2

Deferred income taxes (Tables)

Deferred income taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Major components of tax expense (income) [abstract]
Schedule of Reconciliation of Total Tax Recovery	The effective rate on the Corporation’s loss before income tax differs from the expected amount that would arise using the statutory income tax rates. A reconciliation of the difference is as follows: 2018 2017 $ $ Loss before income taxes (21,935 ) (12,027 ) Income tax rate 30.0 % 31.0 % (6,581 ) (3,728 ) Effect on income taxes of: Non-deductible share-based compensation 507 533 Unrecognized deductible temporary difference and carry forward amounts and experimental development expenditures 6,040 3,184 Other non-deductible items 34 11 Income tax recovery – –
Schedule of Deferred Income Tax	The significant components of the Corporation’s deferred income tax are as follows: 2018 2017 $ $ Deferred income tax liabilities: Intangibles – – Deferred income tax assets: Non-capital losses – – Net deferred income tax liability – –
Schedule of Balance of Temporary Differences for Deferred Income Tax Asset Recognized	The following reflects the balance of temporary differences for which no deferred income tax asset has been recognized: 2018 2017 $ $ Non-capital losses 63,230 43,719 Scientific research and experimental development expenditures 20,096 13,906 Non-refundable investment tax credits 3,832 2,801 Deductible share issuance costs 2,028 1,846 Long-term debt 7,612 6,243 Property and equipment 725 1,144
Schedule of Non-Capital Losses	As at December 31, 2018, the Corporation had approximately $63,230 in losses available to reduce future taxable income. The benefit of these losses has not been recorded in the accounts as realization is not considered probable. These losses may be claimed no later than: $ For the year ending December 31, 2025 1,000 2026 1,100 2027 1,470 2028 1,770 2029 660 2030 2,640 2031 5,180 2032 4,110 2033 4,270 2034 3,400 2035 7,560 2036 5,100 2037 6,700 2038 18,270 63,230

Capital management (Tables)

Capital management (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of capital management [Abstract]
Schedule of Capital Management	2018 2017 $ $ Total long-term debt 8,150 6,537 Less: Cash and cash equivalents (14,895 ) (14,909 ) Net debt (6,745 ) (8,372 ) Equity 4,317 6,343 Total capital (2,428 ) (2,029 )

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
Schedule of Fair Value of Financial Instruments	The following table sets out the approximate fair values of financial instruments as at the consolidated statements of financial position date with relevant comparatives: 2018 2017 Carrying Carrying value Fair value value Fair value $ $ $ $ Cash and cash equivalents 14,895 14,895 14,909 14,909 Amounts receivable 780 780 110 110 Accounts payable and accrued liabilities 7,557 7,557 2,741 2,741 Amounts due to directors 49 49 21 21 Long-term debt 8,150 8,150 6,537 6,537
Schedule of Contractual Maturities for Long-Term Debt Repayable	The following table outlines the contractual maturities for long-term debt repayable based on a percentage of revenues for the Corporation’s financial liabilities. The long-term debt is comprised of the contributions received described in note 11, less amounts that have been repaid as at December 31, 2018: Total Year 1 Years 2 to 3 Years 4 to 5 After 5 years $ $ $ $ $ Accounts payable and accrued liabilities 7,575 7,575 – – – Amounts due to directors 49 49 – – – Short term and low value leases 66 18 27 21 Long-term leases 2,398 275 533 518 1,072 Long-term debt 15,612 264 5,324 142 9,882 25,700 8,181 5,884 681 10,954

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of contingent liabilities [abstract]
Schedule of Minimum Annual Payments Under Long-Term Lease Agreements for Office Premises and Equipment	The minimum annual payments under long-term lease agreements for office premises and equipment expiring over the next five years are as follows: $ Year ending December 31, 2019 257 2020 253 2021 253 2022 251 2023 247

Expenses by nature (Tables)

Expenses by nature (Tables)	12 Months Ended
	Dec. 31, 2018
Expenses
Schedule of Expenses by Nature	2018 2017 $ $ Salaries, wages and benefits 5,945 4,025 Other research and development expenditures, including clinical costs 8,398 3,045 Professional and consulting fees 1,987 1,231 Travel 550 225 Office, rent and telecommunications 586 414 Insurance 444 81 Marketing, communications and investor relations 1,370 1,154 Depreciation 325 140 Stock-based compensation 1,182 571 Deferred share unit compensation 508 1,147 Other 800 329 Accreted interest 1,385 966 Research and development tax credits (1,027 ) (537 ) Government assistance (35 ) (542 ) 22,418 12,249

Compensation of key management

Compensation of key management (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
Schedule of Compensation Awarded to Key Management	Key management includes the Corporation’s Directors, the Chief Executive Officer, the Chief Financial Officer, and the Chief Medical Officer. Compensation awarded to key management is summarized as follows: 2018 2017 $ $ Salaries and other benefits 1,651 1,329 Stock-based compensation 2,121 792 3,772 2,121

New standards and interpretat_3

New standards and interpretations adopted January 1, 2018 (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018CAD ($)
New Standards And Interpretations Adopted January 1 2018 Schedule Of Operating Lease Commitment
Carrying value of leased asset	$ 0
Leased assets	87
Leased liabilities	$ 87
Lease applied rate	11.00%
New office related expense	$ 2,262

New standards and interpretat_4

New standards and interpretations adopted January 1, 2018 (Schedule of Operating Lease Commitment) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018CAD ($)
New Standards And Interpretations Adopted January 1 2018 Schedule Of Operating Lease Commitment
Operating lease commitment as at December 31, 2017	$ 275	[1]
Recognition exemption for:
Short-term leases	(131)
Leases of low value assets	(14)
Commitments attributable to non-lease components	(65)
Extension option reasonably certain to be recognized	51	[2]
Operating lease commitment as at December 31, 2018	116
Discounted using the incremental borrowing rate at January 1, 2018	(29)
Lease liability recognized at January 1, 2018	$ 87
[1]	Does not include $2,262 related to new office space for which the lease commencement date was June 1, 2018.
[2]	The Corporation has applied the transitional provision of IFRS 16 that allows the use of hindsight in determining the lease term if the contract contains an option to extend the lease.

Significant accounting polici_4

Significant accounting policies, judgments and estimation uncertainty (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about borrowings [line items]
Foreign exchange gain loss	$ 139	$ 10
Vesting period	Stock options vest over three years (33 1/3% per year) and expire after five years.
Government assistance	$ 7	10
Long-term debt	$ 8,069	$ 6,476
Percentage of increase or decrease in total forecasted revenue	10.00%
Forecasted revenue
Period of forecasted revenue	two years
AIF loans [Member]
Disclosure of detailed information about borrowings [line items]
Discount rate on loans	35.00%
Weighted average discount rate	higher by 10%, or lower by 10%
Long-term debt	$ 1,440
Loans payable
AIF loans [Member] | Bottom of range [Member]
Disclosure of detailed information about borrowings [line items]
Long-term debt	728
AIF loans [Member] | Top of range [Member]
Disclosure of detailed information about borrowings [line items]
Long-term debt	1,036
Loans payable	$ 3,193
Province loan [Member]
Disclosure of detailed information about borrowings [line items]
Discount rate on loans	11.00%
Province loan [Member] | Bottom of range [Member]
Disclosure of detailed information about borrowings [line items]
Discount rate on loans	6.00%
Long-term debt	$ 325
Province loan [Member] | Top of range [Member]
Disclosure of detailed information about borrowings [line items]
Discount rate on loans	16.00%
Long-term debt	$ 353
Province loan [Member] | Weighted average [Member]
Disclosure of detailed information about borrowings [line items]
Discount rate on loans	5.00%

Significant accounting polici_5

Significant accounting policies, judgments and estimation uncertainty (Schedule of Depreciation Rate) (Details)	12 Months Ended
	Dec. 31, 2018
Computer equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Rate of depreciation of property and equipment	30%
Computer software [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Rate of depreciation of property and equipment	100%
Furniture and fixtures [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Rate of depreciation of property and equipment	20%
Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Rate of depreciation of property and equipment	20%
Leasehold improvements and leased premises [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Rate of depreciation of property and equipment	straight-line

Amounts receivable (Schedule of

Amounts receivable (Schedule of Amounts Receivable) (Details) - CAD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Trade and other current receivables [abstract]
Amounts due from government assistance and government loans	$ 7	$ 10
Sales tax receivable	557	151
Revenue from subcontracts	33	10
Other	740	90
Amounts receivable (note 5)	$ 1,337	$ 261

Property and equipment (Schedul

Property and equipment (Schedule of Property and Equipment) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about property, plant and equipment [line items]
Opening net book value	$ 563	$ 316
Additions	2,666	387
Disposals
Cost	(107)	(9)
Accumulated depreciation	85	9
Depreciation for the year	(325)	(140)
Closing net book value	2,883	563
Computer equipment and software [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net book value	66	43
Additions	79	73
Disposals
Cost	(9)	(9)
Accumulated depreciation	7	9
Depreciation for the year	(47)	(50)
Closing net book value	96	66
Furniture and fixtures [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net book value	27	17
Additions	171	15
Disposals
Cost	(61)
Accumulated depreciation	47
Depreciation for the year	(21)	(5)
Closing net book value	163	27
Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net book value	459	256
Additions	217	282
Disposals
Cost	(37)
Accumulated depreciation	31
Depreciation for the year	(112)	(79)
Closing net book value	558	459
Leased premises [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net book value
Additions	1,417
Disposals
Cost
Accumulated depreciation
Depreciation for the year	(94)
Closing net book value	1,323
Leasehold improvements and leased premises [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening net book value	11
Additions	782	17
Disposals
Cost
Accumulated depreciation
Depreciation for the year	(50)	(6)
Closing net book value	$ 743	$ 11

Property and equipment (Sched_2

Property and equipment (Schedule of Property and Equipment Net Book Value) (Details) - CAD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	$ 2,883	$ 563	$ 316
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	4,032	1,473
Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	(1,149)	(910)
Computer equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	96	66	43
Computer equipment [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	275	205
Computer equipment [Member] | Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	(179)	(139)
Furniture and fixtures [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	163	27	17
Furniture and fixtures [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	194	85
Furniture and fixtures [Member] | Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	(31)	(58)
Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	558	459	256
Laboratory equipment [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	1,346	1,166
Laboratory equipment [Member] | Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	(788)	(707)
Leased premises [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	1,323
Leased premises [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	1,417
Leased premises [Member] | Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	(94)
Leasehold improvements and leased premises [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	743	11
Leasehold improvements and leased premises [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	800	17
Leasehold improvements and leased premises [Member] | Accumulated depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property and equipment	$ (57)	$ (6)

Accounts payable and accrued _3

Accounts payable and accrued liabilities (Schedule of Accounts Payable and Accrued Liabilities) (Details) - CAD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Trade and other current payables [abstract]
Trade payables	$ 5,282	$ 1,683
Accrued liabilities	2,275	1,057
Payroll taxes	18	20
Accounts payable and accrued liabilities	$ 7,575	$ 2,760

Lease obligation (Details)

Lease obligation (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of finance lease and operating lease by lessee [abstract]
Discounted incremental borrowing rate	11.00%
Right of use assets in property, plant and equipment	$ 1,417

Lease obligation (Schedule of L

Lease obligation (Schedule of Lease Obligation) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018CAD ($)
Disclosure of finance lease and operating lease by lessee [abstract]
Balance - December 31, 2017
Leases recognized upon transition to IFRS 16	87
Additions	1,291
Repayment of lease obligation	(74)
Accreted interest	94
Balance - December 31, 2018	1,398
Less: Current portion	(90)
Non-current portion	$ 1,308

Deferred share units (DSUs) (Na

Deferred share units (DSUs) (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Deferred Share Units Dsus Schedule Of Deferred Share Units
DSU common shares	468,750
Deferred share units	$ 1,436	$ 1,371
Compensation expense	$ 508	$ 325

Deferred share units (DSUs) (Sc

Deferred share units (DSUs) (Schedule of Deferred Share Units) (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Deferred Share Units Dsus Schedule Of Deferred Share Units
Opening balance	186,330	101,563
Granted	97,072	84,767
Redeemed	(59,798)
Closing balance	223,604	186,330

Amounts due to directors (Detai

Amounts due to directors (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of amounts due to directors [Abstract]
Directors' fees and attendance fees	$ 206	$ 163
Amounts due to directors	$ 49	$ 21

Long-term debt (Narrative) (Det

Long-term debt (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about borrowings [line items]
Repayment of contributions received	$ 15,234	$ 15,007
Percentage of required to repay of outstanding principal of loan	40.00%
Repayment borrowings term	In August 2017, the Corporation received a two-year extension of the maturity of the Province loan. The original maturity date of the loan was August 9, 2018 and is now August 9, 2020. The annual interest rate remains at the Province's cost of funds plus 1 per cent.
Cash flow from operations	$ (17,177)	$ (8,996)
Province loan [Member]
Disclosure of detailed information about borrowings [line items]
Cash flow from operations	$ 1,500,000

Long-term debt (Schedule of Lon

Long-term debt (Schedule of Long-Term debt) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 8,150	$ 6,537	$ 6,149
Less: Current portion	81	61
Long-term debt	$ 8,069	6,476
Repayment borrowings term	In August 2017, the Corporation received a two-year extension of the maturity of the Province loan. The original maturity date of the loan was August 9, 2018 and is now August 9, 2020. The annual interest rate remains at the Province's cost of funds plus 1 per cent.
Atlantic Canada Opportunities Agency [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 1,202	758
Repayment start date	December 1, 2008
Repayment borrowings term	Annual repayments, commencing December 1, 2008, are calculated as a percentage of gross revenue for the preceding fiscal year, at 2% when gross revenues are less than $5,000 and 5% when gross revenues are greater than $5,000.
Proceeds from borrowings net	$ 3,744	3,747
Atlantic Canada Opportunities Agency [Member] | Top of range [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	3,786
ACOA Atlantic Innovation Fund [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 1,034	651
Repayment start date	December 1, 2011
Repayment borrowings term	Annual repayments, commencing December 1, 2011, are calculated as a percentage of gross revenue for the preceding fiscal year, at 2% when gross revenues are less than $5,000 and 5% when gross revenues are greater than $5,000.
Proceeds from borrowings net	$ 2,995	2,997
ACOA Atlantic Innovation Fund [Member] | Top of range [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	3,000
ACOA Business Development Program [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 238	294
Repayment start date	October 2015
Repayment borrowings term	Repayable in monthly payments beginning October 2015 of $3 until October 2017 and $6 until September 2022.
Proceeds from borrowings net	$ 251	318
ACOA Business Development Program [Member] | Top of range [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	395
ACOA Atlantic Innovation Fund One [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 957	733
Repayment start date	September 1, 2014
Repayment borrowings term	Annual repayments commencing September 1, 2014, are calculated as a percentage of gross revenue from specific product(s) for the preceding fiscal year, at 5% for the first 5 year period and 10%, thereafter.
Proceeds from borrowings net	$ 2,944	2,944
ACOA Atlantic Innovation Fund One [Member] | Top of range [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	2,944
TNC 120-140 Eileen Stubbs Ltd [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 300
Repayment borrowings term	Repayable in monthly payments beginning upon receipt of the final installment of the loan until May 31, 2028.
Proceeds from borrowings net	$ 300
Interest rate	8.00%
TNC 120-140 Eileen Stubbs Ltd [Member] | Top of range [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 300,000
Province of Nova Scotia Secured Loan [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 4,419	4,101
Repayment borrowings term	Repayable on the seventh anniversary date of the first disbursement.
Proceeds from borrowings net	$ 5,000	$ 5,000
Interest rate	1.00%
Province of Nova Scotia Secured Loan [Member] | Top of range [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 5,000

Long-term debt (Schedule of Rep

Long-term debt (Schedule of Repayments of Long-Term Debt) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Borrowings [abstract]
Year ending December 31, 2019	$ 81
2020	4,286
2021	90
2022	78
2023	31
Balance - Beginning of year	6,537	$ 6,149
Borrowings, net of $nil (2017 - $nil) allocated to government assistance	300
Accreted interest	1,385	966
Revaluation of long-term debt		(506)
Repayment of debt	(72)	(72)
Balance - End of year	8,150	6,537
Less: Current portion	81	61
Non-current portion	8,069	6,476
Debt issue costs

Share capital (Narrative) (Deta

Share capital (Narrative) (Details) - CAD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Feb. 15, 2018	Jun. 21, 2017	Dec. 31, 2018	Dec. 31, 2017
Disclosure of classes of share capital [abstract]
Shares reserved to meet outstanding stock options, warrants and deferred share units			1,890,539	3,771,968
Shares issued in public offering	2,246,094	2,403,846
Shares issued price per share in public offering	$ 6.40	$ 4.16
Proceeds from public offering	$ 14,375	$ 10,000	$ 14,375	$ 10,000
Share issue costs	1,480	1,197	(1,480)	(1,197)
Share issue costs including cash costs	863	600	1,148	990
Professional fees and regulatory costs	$ 285	$ 391	$ 1,987	$ 1,231
Compensation warrants issued to agents	134,766	144,231
Compensation warrants issued to agents, value	$ 332	$ 208
Warrants exercise price per share	$ 6.53	$ 4.22
Warrants term	24 months	24 months
Warrants expiration date	February 15, 2020	June 21, 2019

Share capital (Schedule of Shar

Share capital (Schedule of Share Capital) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of classes of share capital [line items]
Balance	$ 6,343	$ 6,983
Stock options exercised	391	108
Warrants exercised	4,889	1,697
Balance	4,317	6,343
Share Capital [Member]
Disclosure of classes of share capital [line items]
Balance	$ 70,113	$ 58,154
Issued and outstanding Begning Balance, shares	40,319,941	36,817,328
Issued for cash, net of issuance costs	$ 12,895	$ 8,803
Issued for cash, net of issuance costs, shares	2,246,094	2,403,846
Stock options exercised	$ 1,444	$ 1,265
Stock options exercised, shares	480,754	316,538
DSUs redeemed	$ 220
DSUs redeemed, shares	29,713
Warrants exercised	$ 5,480	$ 1,891
Warrants exercised, shares	2,029,899	782,229
Balance	$ 90,152	$ 70,113
Issued and outstanding Ending Balance, shares	45,106,401	40,319,941

Contributed surplus (Narrative)

Contributed surplus (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018CAD ($)shares	Dec. 31, 2017CAD ($)shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting terms of options	Stock options vest over three years (33 1/3% per year) and expire after five years.
Stock Options granted | shares	619,505	266,814
Weighted average exercise price	$ 6.65	$ 2.4
Proceeds from options exercised	391,000	$ 109,000
Weighted average exercise price of options exercisable	$ 2.33
Stock option plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maximum number of common shares issuable under the Plan | shares	3,437,500
Stock options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Terms of options	The term of the option is determined by the Board of Directors, not to exceed ten years from the date of grant, however, the majority of options expire in five years.
Vesting terms of options	The vesting of the options is determined by the Board and beginning, January 1, 2018, is typically 33 1/3% every year after the date of grant.
Cashless options exercised | shares	443,748	548,833
Options Issued | shares	297,626	238,130
Proceeds from options exercised	$ 975,000	$ 1,227,000
Weighted average exercise price of options exercisable	$ 4.09	$ 2.25
Stock options [Member] | Employees and consultants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Terms of options	five years	five years
Stock Options granted | shares	619,505	266,813
Weighted average exercise price	$ 6.65	$ 2.4
Stock Options granted, value	2,378,000	425,000
Weighted average grant date value per share	$ 3.84	$ 1.6
Corporation stock option plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maximum number of common shares issuable under the Plan | shares	3,437,500

Contributed surplus (Schedule o

Contributed surplus (Schedule of Contributed Surplus) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Balance	$ 6,343	$ 6,983
Share-based compensation - stock options vested	1,182	571
Stock options exercised	391	108
Balance	4,317	6,343
Contributed Surplus [Member]
Balance	6,375	6,961
Share-based compensation - stock options vested	1,182	571
Warrants expired
Stock options exercised	(1,053)	(1,157)
Balance	$ 6,504	$ 6,375

Contributed surplus (Schedule_2

Contributed surplus (Schedule of Weighted Average Assumptions) (Details) - Years	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Risk-free interest rate	2.02%	2.70%
Expected volatility	77.00%	98.00%
Expected life (years)	4.2	4.4
Forfeiture rate	5.00%	4.00%

Contributed surplus (Schedule_3

Contributed surplus (Schedule of Option Activity) (Details)		12 Months Ended
		Dec. 31, 2018CAD ($)shares	Dec. 31, 2017CAD ($)shares
Number
Outstanding - Beginning of year | shares		1,498,052	1,961,791
Granted | shares		619,505	266,814
Exercised | shares	[1]	(626,875)	(627,256)
Expired | shares		(5,569)	(64,068)
Forfeited | shares		(10,636)	(39,229)
Outstanding - End of year | shares		1,474,477	1,498,052
Weighted average exercise price
Outstanding - Beginning of year | $		$ 2.26	$ 2.23
Granted | $		6.65	2.4
Exercised | $		2.18	2.21
Expired | $		1.8	2.19
Forfeited | $		4.92	2.37
Outstanding - End of year | $		$ 4.12	$ 2.26
[1]	Of the 626,875 (2017 - 627,256) options exercised, 443,748 (2017 - 548,833) elected the cashless exercise, under which 297,626 shares (2017 - 238,130) were issued. These options would have otherwise been exercisable for proceeds of $975 (2017 - $1,227) on the exercise date.

Contributed surplus (Schedule_4

Contributed surplus (Schedule of Options Outstanding) (Details)	Dec. 31, 2018CAD ($)sharesYears	Dec. 31, 2017CAD ($)shares	Dec. 31, 2016CAD ($)shares
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options outstanding, Number | shares	1,474,477	1,498,052	1,961,791
Options outstanding, Weighted average exercise price | $	$ 4.12	$ 2.26	$ 2.23
Options outstanding, Weighted average remaining contractual life (years) | Years	2.98
Options exercisable, Number | shares	860,753
Options exercisable, Weighted average exercise price | $	$ 2.33
Options exercisable, Weighted average remaining contractual life (years) | Years	2.11
Exercise price range 1.98 - 2.29 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options outstanding, Number | shares	285,939
Options outstanding, Weighted average exercise price | $	$ 2.08
Options outstanding, Weighted average remaining contractual life (years) | Years	2.16
Options exercisable, Number | shares	285,939
Options exercisable, Weighted average exercise price | $	$ 2.08
Options exercisable, Weighted average remaining contractual life (years) | Years	2.16
Exercise price range 2.30 - 2.38 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options outstanding, Number | shares	259,377
Options outstanding, Weighted average exercise price | $	$ 2.37
Options outstanding, Weighted average remaining contractual life (years) | Years	1.48
Options exercisable, Number | shares	259,377
Options exercisable, Weighted average exercise price | $	$ 2.37
Options exercisable, Weighted average remaining contractual life (years) | Years	1.48
Exercise price range 2.39 - 3.01 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options outstanding, Number | shares	310,125
Options outstanding, Weighted average exercise price | $	$ 2.5
Options outstanding, Weighted average remaining contractual life (years) | Years	2.63
Options exercisable, Number | shares	310,125
Options exercisable, Weighted average exercise price | $	$ 2.5
Options exercisable, Weighted average remaining contractual life (years) | Years	2.63
Exercise price range 3.02 - 6.72 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options outstanding, Number | shares	400,625
Options outstanding, Weighted average exercise price | $	$ 6.36
Options outstanding, Weighted average remaining contractual life (years) | Years	4.17
Options exercisable, Number | shares	5,312
Options exercisable, Weighted average exercise price | $	$ 3.2
Options exercisable, Weighted average remaining contractual life (years) | Years	0.25
Exercise price range 6.73 - 7.39 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options outstanding, Number | shares	218,411
Options outstanding, Weighted average exercise price | $	$ 7.09
Options outstanding, Weighted average remaining contractual life (years) | Years	4.17
Options exercisable, Number | shares
Options exercisable, Weighted average exercise price | $
Options exercisable, Weighted average remaining contractual life (years) | Years

Warrants (Schedule of Warrant A

Warrants (Schedule of Warrant Activity) (Details)		12 Months Ended
		Dec. 31, 2018CAD ($)shares	Dec. 31, 2017CAD ($)shares
Number
Outstanding - Beginning of year | shares		1,498,052	1,961,791
Granted | shares		619,505	266,814
Exercised | shares	[1]	(626,875)	(627,256)
Outstanding - End of year | shares		1,474,477	1,498,052
Weighted average exercise price
Outstanding - Beginning of year		$ 2.26	$ 2.23
Granted		6.65	2.4
Exercised		$ 2.18	$ 2.21
Warrants [Member]
Number
Outstanding - Beginning of year | shares		2,087,598	2,725,596
Granted | shares		134,766	144,231
Exercised | shares		(2,029,905)	(782,229)
Outstanding - End of year | shares		192,459	2,087,598
Weighted average exercise price
Outstanding - Beginning of year		$ 2.46	$ 2.27
Granted		6.53	4.22
Exercised		2.41	2.18
Amount
Opening balance		674,000	660,000
Granted		332,000	208,000
Exercised		(591,000)	(194,000)
Closing balance		415,000	674,000
Weighted average grant date value per warrant of warrants issued		$ 2.47	$ 1.44
[1]	Of the 626,875 (2017 - 627,256) options exercised, 443,748 (2017 - 548,833) elected the cashless exercise, under which 297,626 shares (2017 - 238,130) were issued. These options would have otherwise been exercisable for proceeds of $975 (2017 - $1,227) on the exercise date.

Warrants (Schedule of Weighted

Warrants (Schedule of Weighted Average Assumptions) (Details) - Years	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate	2.02%	2.70%
Expected volatility	77.00%	98.00%
Expected life (years)	4.2	4.4
Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate	1.84%	2.70%
Expected volatility	68.00%	72.00%
Expected dividend yield
Expected life (years)	2	2

Deferred income taxes (Schedule

Deferred income taxes (Schedule of Reconciliation of Total Tax Recovery) (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Major components of tax expense (income) [abstract]
Loss before income taxes	$ (21,935)	$ (12,027)
Income tax rate	30.00%	31.00%
Accounting profit	$ (6,581)	$ (3,728)
Effect on income taxes of:
Non-deductible share-based compensation	507	533
Unrecognized deductible temporary difference and carry forward amounts and experimental development expenditures	6,040	3,184
Other non-deductible items	34	11
Tax expense (income)

Deferred income taxes (Schedu_2

Deferred income taxes (Schedule of Deferred Income Tax) (Details) - CAD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred income tax liabilities:
Intangibles
Deferred income tax assets:
Non-capital losses
Net deferred income tax liability

Deferred income taxes (Schedu_3

Deferred income taxes (Schedule of Balance of Temporary Differences for Deferred Income Tax Asset Recognized) (Details) - CAD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Major components of tax expense (income) [abstract]
Non-capital losses	$ 63,230	$ 43,719
Scientific research and experimental development expenditures	20,096	13,906
Non-refundable investment tax credits	3,832	2,801
Deductible share issuance costs	2,028	1,846
Long-term debt	7,612	6,243
Property and equipment	$ 725	$ 1,144

Deferred income taxes (Schedu_4

Deferred income taxes (Schedule of Non-Capital Losses) (Details) - CAD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	$ 63,230	$ 43,719
2025 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	1,000
2026 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	1,100
2027 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	1,470
2028 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	1,770
2029 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	660
2030 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	2,640
2031 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	5,180
2032 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	4,110
2033 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	4,270
2034 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	3,400
2035 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	7,560
2036 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	5,100
2037 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	6,700
2038 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	$ 18,270

Capital management (Schedule of

Capital management (Schedule of Capital management) (Details) - CAD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of capital management [Abstract]
Total long-term debt	$ 8,150	$ 6,537	$ 6,149
Less: Cash and cash equivalents	(14,895)	(14,909)	(13,547)
Net debt	(6,745)	(8,372)
Equity	4,317	6,343	$ 6,983
Total capital	$ (2,428)	$ (2,029)

Financial instruments (Narrativ

Financial instruments (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about financial instruments [line items]
Total amount drawn down		$ (81)	$ (61)
Principal debt payments		72	72
Amounts receivable		1,337	261
Equity		(4,317)	(6,343)	$ (6,983)
Cash and cash equivalents		14,895	14,909	13,547
Foreign exchange gain loss		$ 139	10
Percentage of Foreign exchange gain loss		1.00%
Deficit [Member]
Disclosure of detailed information about financial instruments [line items]
Equity		$ 92,754	70,819	$ 58,792
Interest rate risk [Member]
Disclosure of detailed information about financial instruments [line items]
Total amount drawn down		5,000	$ 5,000
Interest payments		$ 148
Loan terms		84 months
Interest rate risk [Member] | Principal debt payments [Member]
Disclosure of detailed information about financial instruments [line items]
Interest payments	$ 21
Principal debt payments	67
Interest rate risk [Member] | Principal debt payments [Member] | Transaction One [Member]
Disclosure of detailed information about financial instruments [line items]
Principal debt payments	$ 5
Fixed interest rate [Member] | Interest rate risk [Member]
Disclosure of detailed information about financial instruments [line items]
Interest rate		1.00%
Fixed interest rate [Member] | Interest rate risk [Member] | Principal debt payments [Member]
Disclosure of detailed information about financial instruments [line items]
Interest rate	8.00%

Financial instruments (Schedule

Financial instruments (Schedule of Fair Value of Financial Instruments) (Details) - CAD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	$ 14,895	$ 14,909	$ 13,547
Amounts receivable	1,337	261
Accounts payable and accrued liabilities	7,575	2,760
Amounts due to directors	49	21
Long-term debt	8,069	6,476
Carrying value [Member]
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	14,895	14,909
Amounts receivable	780	110
Accounts payable and accrued liabilities	7,557	2,741
Amounts due to directors	49	21
Long-term debt	8,150	6,537
Fair value [Member]
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	14,895	14,909
Amounts receivable	780	110
Accounts payable and accrued liabilities	7,557	2,741
Amounts due to directors	49	21
Long-term debt	$ 8,150	$ 6,537

Financial instruments (Schedu_2

Financial instruments (Schedule of Contractual Maturities for Long-Term Debt Repayable) (Details) - CAD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of financial liabilities [line items]
Accounts payable and accrued liabilities	$ 7,575	$ 2,760
Amounts due to directors	49	21
Long-term leases	1,308
Long-term debt	8,069	$ 6,476
Total [Member]
Disclosure of financial liabilities [line items]
Accounts payable and accrued liabilities	7,575
Amounts due to directors	49
Short term and low value leases	66
Long-term leases	2,398
Long-term debt	15,612
Financial liabilities	25,700
Year 1 [Member]
Disclosure of financial liabilities [line items]
Accounts payable and accrued liabilities	7,575
Amounts due to directors	49
Short term and low value leases	18
Long-term leases	275
Long-term debt	264
Financial liabilities	8,181
Years 2 to 3 [Member]
Disclosure of financial liabilities [line items]
Accounts payable and accrued liabilities
Amounts due to directors
Short term and low value leases	27
Long-term leases	533
Long-term debt	5,324
Financial liabilities	5,884
Years 4 to 5 [Member]
Disclosure of financial liabilities [line items]
Accounts payable and accrued liabilities
Amounts due to directors
Short term and low value leases	21
Long-term leases	518
Long-term debt	142
Financial liabilities	681
After 5 years [Member]
Disclosure of financial liabilities [line items]
Accounts payable and accrued liabilities
Amounts due to directors
Long-term leases	1,072
Long-term debt	9,882
Financial liabilities	$ 10,954

Commitments (Schedule of Minimu

Commitments (Schedule of Minimum Annual Payments Under Long-Term Lease Agreements for Office Premises and Equipment) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018CAD ($)
2019 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual payments under long-term lease agreements for office premises and equipment expiring over the next five years	$ 257
2020 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual payments under long-term lease agreements for office premises and equipment expiring over the next five years	253
2021 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual payments under long-term lease agreements for office premises and equipment expiring over the next five years	253
2022 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual payments under long-term lease agreements for office premises and equipment expiring over the next five years	251
2023 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual payments under long-term lease agreements for office premises and equipment expiring over the next five years	$ 247

Related party transactions (Det

Related party transactions (Details)	12 Months Ended
	Dec. 31, 2017CAD ($)
Disclosure of transactions between related parties [abstract]
Related party transactions

Expenses by nature (Schedule of

Expenses by nature (Schedule of Expenses by Nature) (Details) - CAD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Feb. 15, 2018	Jun. 21, 2017	Dec. 31, 2018	Dec. 31, 2017
Expenses
Salaries, wages and benefits			$ 5,945	$ 4,025
Other research and development expenditures, including clinical costs			8,398	3,045
Professional and consulting fees	$ 285	$ 391	1,987	1,231
Travel			550	225
Office, rent and telecommunications			586	414
Insurance			444	81
Marketing, communications and investor relations			1,370	1,154
Depreciation			325	140
Stock-based compensation			1,182	571
Deferred share unit compensation			508	1,147
Other			800	329
Accreted interest			1,385	966
Research and development tax credits			(1,027)	(537)
Government assistance			(35)	(542)
Total Expenses			$ 22,418	$ 12,249

Compensation of key managemen_2

Compensation of key management (Schedule of Compensation Awarded to Key Management) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
Salaries and other benefits	$ 1,651	$ 1,329
Stock-based compensation	2,121	792
Total	$ 3,772	$ 2,121

Share consolidation (Details)

Share consolidation (Details)	May 02, 2018
Disclosure of share consolidation [Abstract]
Share consolidation	one new common share for every 3.2 currently outstanding shares.

Subsequent event (Details)

Subsequent event (Details) $ / shares in Units, $ in Thousands		Mar. 11, 2019CAD ($)shares$ / shares	Mar. 06, 2019CAD ($)$ / sharesshares	Feb. 15, 2018CAD ($)$ / sharesshares	Jun. 21, 2017CAD ($)$ / sharesshares	Dec. 31, 2018CAD ($)shares	Dec. 31, 2017CAD ($)shares
Disclosure of non-adjusting events after reporting period [line items]
Shares issued in public offering | shares				2,246,094	2,403,846
Shares issued price per share in public offering | $ / shares				$ 6.40	$ 4.16
Proceeds from public offering				$ 14,375	$ 10,000	$ 14,375	$ 10,000
Exercised options to purchase common stock | shares	[1]					626,875	627,256
Proceeds from options exercises						$ 391	$ 109
Commissions and offering expenses				$ 863	$ 600	$ 1,148	$ 990
Shares issued in public offering [Member]
Disclosure of non-adjusting events after reporting period [line items]
Shares issued in public offering | shares			4,900,000
Shares issued price per share in public offering | $ / shares			$ 5.45
Proceeds from public offering			$ 26,700
Underwriters [Member]
Disclosure of non-adjusting events after reporting period [line items]
Exercised options to purchase common stock | shares		504,855
Exercise price of option | $ / shares		$ 5.45
Additional proceeds from options exercises		$ 2,750
Proceeds from options exercises		29,460
Commissions and offering expenses		$ 2,000
[1]	Of the 626,875 (2017 - 627,256) options exercised, 443,748 (2017 - 548,833) elected the cashless exercise, under which 297,626 shares (2017 - 238,130) were issued. These options would have otherwise been exercisable for proceeds of $975 (2017 - $1,227) on the exercise date.